

GLOBAL JOURNAL

OF MEDICAL RESEARCH: H

Orthopedic & Musculoskeletal System

Mc-Cune Albright Syndrome

Femoral Supracondylar Amputation

Highlights

Preventing Phantom Limb Pain

Advanced Ayurvedic Detox Program

Discovering Thoughts, Inventing Future

VOLUME 20 ISSUE 1 VERSION 1.0

© 2001-2020 by Global Journal of Medical Research, USA



GLOBAL JOURNAL OF MEDICAL RESEARCH: H
ORTHOPEDIC AND MUSCULOSKELETAL SYSTEM

GLOBAL JOURNAL OF MEDICAL RESEARCH: H
ORTHOPEDIC AND MUSCULOSKELETAL SYSTEM

VOLUME 20 ISSUE 1 (VER. 1.0)

OPEN ASSOCIATION OF RESEARCH SOCIETY

© Global Journal of Medical Research. 2020.

All rights reserved.

This is a special issue published in version 1.0 of "Global Journal of Medical Research." By Global Journals Inc.

All articles are open access articles distributed under "Global Journal of Medical Research"

Reading License, which permits restricted use. Entire contents are copyright by of "Global Journal of Medical Research" unless otherwise noted on specific articles.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission.

The opinions and statements made in this book are those of the authors concerned. Ultraculture has not verified and neither confirms nor denies any of the foregoing and no warranty or fitness is implied.

Engage with the contents herein at your own risk.

The use of this journal, and the terms and conditions for our providing information, is governed by our Disclaimer, Terms and Conditions and Privacy Policy given on our website <http://globaljournals.us/terms-and-condition/menu-id-1463/>

By referring / using / reading / any type of association / referencing this journal, this signifies and you acknowledge that you have read them and that you accept and will be bound by the terms thereof.

All information, journals, this journal, activities undertaken, materials, services and our website, terms and conditions, privacy policy, and this journal is subject to change anytime without any prior notice.

Incorporation No.: 0423089
License No.: 42125/022010/1186
Registration No.: 430374
Import-Export Code: 1109007027
Employer Identification Number (EIN):
USA Tax ID: 98-0673427

Global Journals Inc.

(A Delaware USA Incorporation with "Good Standing"; **Reg. Number: 0423089**)

Sponsors: Open Association of Research Society

Open Scientific Standards

Publisher's Headquarters office

Global Journals® Headquarters
945th Concord Streets,
Framingham Massachusetts Pin: 01701,
United States of America

USA Toll Free: +001-888-839-7392

USA Toll Free Fax: +001-888-839-7392

Offset Typesetting

Global Journals Incorporated
2nd, Lansdowne, Lansdowne Rd., Croydon-Surrey,
Pin: CR9 2ER, United Kingdom

Packaging & Continental Dispatching

Global Journals Pvt Ltd
E-3130 Sudama Nagar, Near Gopur Square,
Indore, M.P., Pin:452009, India

Find a correspondence nodal officer near you

To find nodal officer of your country, please
email us at local@globaljournals.org

eContacts

Press Inquiries: press@globaljournals.org
Investor Inquiries: investors@globaljournals.org
Technical Support: technology@globaljournals.org
Media & Releases: media@globaljournals.org

Pricing (Excluding Air Parcel Charges):

Yearly Subscription (Personal & Institutional)
250 USD (B/W) & 350 USD (Color)

EDITORIAL BOARD

GLOBAL JOURNAL OF MEDICAL RESEARCH

Dr. Apostolos Ch. Zarros

DM, Degree (Ptychio) holder in Medicine,
National and Kapodistrian University of Athens
MRes, Master of Research in Molecular Functions in
Disease, University of Glasgow FRNS, Fellow, Royal
Numismatic Society Member, European Society for
Neurochemistry Member, Royal Institute of Philosophy
Scotland, United Kingdom

Dr. William Chi-shing Cho

Ph.D.,
Department of Clinical Oncology
Queen Elizabeth Hospital
Hong Kong

Dr. Alfio Ferlito

Professor Department of Surgical Sciences
University of Udine School of Medicine, Italy

Dr. Michael Wink

Ph.D., Technical University Braunschweig, Germany
Head of Department Institute of Pharmacy and Molecular
Biotechnology, Heidelberg University, Germany

Dr. Jixin Zhong

Department of Medicine, Affiliated Hospital of
Guangdong Medical College, Zhanjiang, China, Davis
Heart and Lung Research Institute, The Ohio State
University, Columbus, OH 43210, US

Dr. Pejdic Ana

Assistant Medical Faculty Department of Periodontology
and Oral Medicine University of Nis, Serbia

Rama Rao Ganga

MBBS
MS (Universty of Health Sciences, Vijayawada, India)
MRCS (Royal College of Surgeons of Edinburgh, UK)
United States

Dr. Ivandro Soares Monteiro

M.Sc., Ph.D. in Psychology Clinic, Professor University of
Minho, Portugal

Dr. Izzet Yavuz

MSc, Ph.D., D Ped Dent.
Associate Professor, Pediatric Dentistry Faculty of
Dentistry, University of Dicle Diyarbakir, Turkey

Dr. Sanjay Dixit, M.D.

Director, EP Laboratories, Philadelphia VA Medical Center
Cardiovascular Medicine - Cardiac Arrhythmia
Univ of Penn School of Medicine
Web: pennmedicine.org/wagform/MainPage.aspx?

Sanguansak Rerksupphol

Department of Pediatrics Faculty of Medicine
Srinakharinwirot University
NakornNayok, Thailand

Antonio Simone Laganà

M.D. Unit of Gynecology and Obstetrics
Department of Human Pathology in Adulthood and
Childhood "G. Barresi" University of Messina, Italy

Dr. Han-Xiang Deng

MD., Ph.D
Associate Professor and Research Department
Division of Neuromuscular Medicine
Davee Department of Neurology and Clinical
Neurosciences
Northwestern University Feinberg School of Medicine
Web: neurology.northwestern.edu/faculty/deng.html

Dr. Roberto Sanchez

Associate Professor
Department of Structural and Chemical Biology
Mount Sinai School of Medicine
Ph.D., The Rockefeller University
Web: mountsinai.org/

Dr. Feng Feng

Boston University
Microbiology
72 East Concord Street R702
Duke University
United States of America

Dr. Hrushikesh Aphale

MDS- Orthodontics and Dentofacial Orthopedics.
Fellow- World Federation of Orthodontist, USA.

Gaurav Singhal

Master of Tropical Veterinary Sciences, currently
pursuing Ph.D in Medicine

Dr. Pina C. Sanelli

Associate Professor of Radiology
Associate Professor of Public Health
Weill Cornell Medical College
Associate Attending Radiologist
NewYork-Presbyterian Hospital
MRI, MRA, CT, and CTA
Neuroradiology and Diagnostic Radiology
M.D., State University of New York at Buffalo,
School of Medicine and Biomedical Sciences
Web: weillcornell.org/pinasanelli/

Dr. Michael R. Rudnick

M.D., FACP
Associate Professor of Medicine
Chief, Renal Electrolyte and Hypertension Division (PMC)
Penn Medicine, University of Pennsylvania
Presbyterian Medical Center, Philadelphia
Nephrology and Internal Medicine
Certified by the American Board of Internal Medicine
Web: uphs.upenn.edu/

Dr. Seung-Yup Ku

M.D., Ph.D., Seoul National University Medical College,
Seoul, Korea Department of Obstetrics and Gynecology
Seoul National University Hospital, Seoul, Korea

Santhosh Kumar

Reader, Department of Periodontology,
Manipal University, Manipal

Dr. Aarti Garg

Bachelor of Dental Surgery (B.D.S.) M.D.S. in Pedodontics
and Preventive Dentistr Pursuing Phd in Dentistry

<i>Sabreena Safuan</i>	<i>Arundhati Biswas</i>
Ph.D (Pathology) MSc (Molecular Pathology and Toxicology) BSc (Biomedicine)	MBBS, MS (General Surgery), FCPS, MCh, DNB (Neurosurgery)
<i>Getahun Asebe</i>	<i>Rui Pedro Pereira de Almeida</i>
Veterinary medicine, Infectious diseases, Veterinary Public health, Animal Science	Ph.D Student in Health Sciences program, MSc in Quality Management in Healthcare Facilities
<i>Dr. Suraj Agarwal</i>	<i>Dr. Sunanda Sharma</i>
Bachelor of dental Surgery Master of dental Surgery in Oromaxillofacial Radiology. Diploma in Forensic Science & Oodntology	B.V.Sc.& AH, M.V.Sc (Animal Reproduction, Obstetrics & gynaecology), Ph.D.(Animal Reproduction, Obstetrics & gynaecology)
<i>Osama Alali</i>	<i>Shahanawaz SD</i>
PhD in Orthodontics, Department of Orthodontics, School of Dentistry, University of Damascus. Damascus, Syria. 2013 Masters Degree in Orthodontics.	Master of Physiotherapy in Neurology PhD- Pursuing in Neuro Physiotherapy Master of Physiotherapy in Hospital Management
<i>Prabudh Goel</i>	<i>Dr. Shabana Naz Shah</i>
MCh (Pediatric Surgery, Gold Medalist), FISPU, FICS-IS	PhD. in Pharmaceutical Chemistry
<i>Raouf Hajji</i>	<i>Vaishnavi V.K Vedam</i>
MD, Specialty Assistant Professor in Internal Medicine	Master of dental surgery oral pathology
<i>Surekha Damineni</i>	<i>Tariq Aziz</i>
Ph.D with Post Doctoral in Cancer Genetics	PhD Biotechnology in Progress

CONTENTS OF THE ISSUE

- i. Copyright Notice
- ii. Editorial Board Members
- iii. Chief Author and Dean
- iv. Contents of the Issue

1. Pathological Proximal Femoral Fracture in Mc-Cune Albright Syndrome: A Case Report. *1-3*
2. Anterior Bowing of Tibia in an Adult. *5-9*
3. Effectiveness of Perineural Dexmedetomidine and Ropivacaine on Preventing Phantom Limb Pain in Patients Undergoing Femoral Supracondylar Amputation. *11-17*
4. 'Arthrox' an Advanced Ayurvedic Detox Program for Knee Osteoarthritis- A Case Report. *19-22*

- v. Fellows
- vi. Auxiliary Memberships
- vii. Preferred Author Guidelines
- viii. Index



GLOBAL JOURNAL OF MEDICAL RESEARCH: H
ORTHOPEDIC AND MUSCULOSKELETAL SYSTEM
Volume 20 Issue 1 Version 1.0 Year 2020
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Pathological Proximal Femoral Fracture in Mc-Cune Albright Syndrome: A Case Report

By Apoorv Sehgal, Pratyush Shahi & Aarushi Sudan

University College of Medical Sciences

Abstract- A 25-year-old female present to us in the emergency department with atraumatic fracture of the proximal femur. She had a cafe-au-lait spot on the face and gave history of precocious puberty. A skeletal survey showed polyostotic fibrous dysplasia. A clinico-radiological diagnosis of McCune-Albright syndrome was made which was further confirmed on biopsy. An extra-medullary fixation was done and at 6 months follow-up, the fracture had united and the patient could walk without support.

GJMR-H Classification: NLMC Code: WE 175



Strictly as per the compliance and regulations of:



RESEARCH | DIVERSITY | ETHICS

Pathological Proximal Femoral Fracture in McCune Albright Syndrome: A Case Report

Apoorv Sehgal ^α, Pratyush Shahi ^σ & Aarushi Sudan ^ρ

Abstract- A 25-year-old female present to us in the emergency department with atraumatic fracture of the proximal femur. She had a café-au-lait spot on the face and gave history of precocious puberty. A skeletal survey showed polyostotic fibrous dysplasia. A clinico-radiological diagnosis of McCune-Albright syndrome was made which was further confirmed on biopsy. An extra-medullary fixation was done and at 6 months follow-up, the fracture had united and the patient could walk without support.

I. INTRODUCTION

Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) occurs due to somatic gain-of-function mutations of the *GNAS* gene. These mutations cause over activity in the target tissues leading to clinical features that vary in severity and age of onset.¹ Since the disease is rare and can have atypical presentation, the diagnosis can be missed. We report the case of a young female with McCune-Albright syndrome presenting to us with pathological fracture of the proximal femur and highlight the challenges one can face in fixation of such fractures.

II. CASE PRESENTATION

A 25-year-old female patient presented to us with a history of sudden onset of pain in her right hip and inability to bear weight over the affected limb. There was no history of trauma, fever or weight loss. On examination, the right lower extremity was externally rotated and shortened. Movements at the right hip elicited pain. The patient was of short stature and had café-au-lait skin macule with jagged, irregular borders (coast of Maine) on her face with short stature.(Figure 1) On further inquiry, she gave a history of precocious puberty.

Radiographs revealed lytic expansile lesion with ground-glass appearance and thinning of cortex in metaphyseal region of the right proximal femur associated with a pathological subtrochanteric fracture. Other sites like skull, radius and phalanges also had similar lytic lesions.(Figure 2)

Based on clinical and radiological features, a diagnosis of McCune-Albright syndrome with pathological right subtrochanteric fracture was made.

The patient was put on skin traction for the right lower limb and advised to undergo surgery for the subtrochanteric fracture of right femur in view of the nature of the fracture and the requirement of early ambulation. After proper consent, the patient was taken up for surgery. Fracture was reduced on a traction table after opening the fracture area. Biopsy was taken from the fracture site followed by reduction and fixation with distal femoral locking plate of opposite side in reverse configuration. The initial plan was of internal fixation with cephalomedullary nail, but due to very narrow diameter of the medullary canal, an extramedullary fixation had to be done. (Figure 3) The patient was discharged on post-operative day 5 after confirming healthy state of the wound. She was started on partial weight-bearing with crutches at 2 weeks continuing to full weight-bearing at 6 weeks. At 6 months follow-up, the patient could walk without support and with no residual complaints.

Author ^{α σ ρ}: University College of Medical Sciences, Delhi, India.
e-mail: apoorvsehgal2006@gmail.com



Figure1: Showing the cafe-au-lait spot





Figure 2: (A-D) showing lytic ground-glass lesions in the skull, radius, phalanges and proximal femur, (E) showing a pathological subtrochanteric fracture, (F) after fixation

III. DISCUSSION

McCune–Albright syndrome is a rare sporadic disease caused by somatic postzygotic activating mutations in the *GNAS* gene. It is characterised by polyostotic fibrous dysplasia, café-au-lait skin spots and variable hyperfunctional endocrinopathies.²

A fibrous dysplasia lesion predisposes a person to have a pathological fracture and if involving a large area can lead to deformity of the bone. Although a small lesion can be left as such, a larger lesion causing pain or threatening to fracture should be curetted and bone grafted even though there is a high tendency for it to recur. If the site and extent of the lesion necessitates, prophylactic fixation should be done. The management of fibrous dysplasia becomes more complicated when it is associated with extra-skeletal manifestations.^{1,3}

A lesion of the proximal femur causes more pain, fractures and deformity than any other skeletal localization of the disease.²⁻⁵ A pathological fracture of the proximal femur secondary to fibrous dysplasia poses several intra-operative challenges. A surgeon should do proper pre-operative planning and have backup fixation devices. Also, good post-operative wound care and early rehabilitation should be done.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Lichtenstein L. Polyostotic fibrous dysplasia. *Arch surg.* 1938;36:874–898. doi: 10.1001/archsurg.1938.01190230153012.
2. Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. *J*

Bone Miner Res. 2004; 19:571–577. doi: 10.1359/JBMR.0301262

3. Harris WH, Dudley HR, Jr, Barry RJ. The natural history of fibrous dysplasia. An orthopaedic, pathological, and roentgenographic study. *J Bone Joint Surg Am.* 1962; 44-A:207–233. doi: 10.2106/00004623-196244020-00001
4. Stanton RP, Ippolito E, Springfield D, Lindaman L, Wientroub S, Leet A. The surgical management of fibrous dysplasia of bone. *Orphanet J Rare Dis.* 2012;7(Suppl 1):S1. doi: 10.1186/1750-1172-7-S1-S1.
5. O'Sullivan M, Zacharin M. Intramedullary rodding and bisphosphonate treatment of polyostotic fibrous dysplasia associated with the McCune-Albright syndrome. *J Pediatr Orthop.* 2002;22:255–60.



This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: H
ORTHOPEDIC AND MUSCULOSKELETAL SYSTEM
Volume 20 Issue 1 Version 1.0 Year 2020
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Anterior Bowing of Tibia in an Adult

By Pratyush Shahi, Apoorv Sehgal & Aarushi Sudan

University College of Medical Sciences

Abstract- A 35-year-old female presented to us with anterior bowing of her right tibia. The deformity developed in her adolescence and subsequently had not progressed for nearly two decades. The patient had no functional limitation, her only concern being cosmesis. Radiological investigations suggested either fibrous dysplasia or adamantinoma. Biopsy showed fibrous stroma consisting of myxofibrous tissue and woven bone which was confirmatory of fibrous dysplasia. Keeping in mind that it was a dormant benign lesion not hindering with functionality of the limb, it was decided to keep the patient under observation with regular follow-up.

GJMR-H Classification: NLMC Code: WE 168



Strictly as per the compliance and regulations of:



Anterior Bowing of Tibia in an Adult

Pratyush Shahi ^α, Apoorv Sehgal ^σ & Aarushi Sudan ^ρ

Abstract- A 35-year-old female presented to us with anterior bowing of her right tibia. The deformity developed in her adolescence and subsequently had not progressed for nearly two decades. The patient had no functional limitation, her only concern being cosmesis. Radiological investigations suggested either fibrous dysplasia or adamantinoma. Biopsy showed fibrous stroma consisting of myxofibrous tissue and woven bone which was confirmatory of fibrous dysplasia. Keeping in mind that it was a dormant benign lesion not hindering with functionality of the limb, it was decided to keep the patient under observation with regular follow-up.

I. INTRODUCTION

Bowing of tibia can be anterior, anterolateral, anteromedial and posteromedial. Anterior tibial bowing, although rare, can be seen in fibrous dysplasia, osteofibrous dysplasia, adamantinoma, congenital pseudoarthrosis, vitamin D deficiency, syphilis, yaws, Paget's disease of the bone, fluorosis and Weismann-Netter-Stuhl syndrome.

We report a case of anterior tibial bowing in a middle-aged female and aim to highlight the importance

of differentiation between benign fibrous dysplasia, potentially pre-malignant osteofibrous dysplasia and malignant adamantinoma in such a case.

II. CASE PRESENTATION

A 35-year-old female presented to us with an anteriorly bowed tibia of the right side. She had started noticing it at the age of 8 years, after which the deformity had progressed for a period of 10 years. It has now remained quiescent over the last 17 years. She complains of occasional pain in the right leg, but has no functional limitation. The overlying skin was normal with no dilated veins. She has normal local temperature, mild tenderness over the apex of the deformity, a shortening of 1.5 cm on the affected side and the range of motion of the knee and ankle joints on the affected side are comparable to the opposite side. Both feet are comparable in size. There is no distal neurovascular deficit. She doesn't have any other deformity or any hyperpigmentation.





Figure 1: A and B showing anteriorly bowed right leg, fairly good motion at knee and ankle joints with minimal shortening

III. INVESTIGATIONS

X-ray, CT scan and MRI are shown in the figures. Blood investigations were found to be normal.






Figure 2: A-E showing anterior bowing of tibia, diffuse expansion of tibial diaphysis, loss of cortico-medullary junction, homogenous ground glass opacities and areas of cystic licences, narrow zone of transition with no cortical breach or soft tissue component

IV. DIFFERENTIAL DIAGNOSIS

Based on the radiological investigations, fibrous dysplasia and adamantinoma were kept as the two possibilities. Moth-eaten type of bone destruction and cortical thickening favour adamantinoma. Non-involvement of fibula and no osseous breach favour fibrous dysplasia.

V. HISTOPATHOLOGY

Characteristic findings indicative of fibrous dysplasia include fibrous stroma consisting of myxofibrous tissue and woven bone.¹ The histologic diagnosis of adamantinoma is made when epithelial-like cells arranged in palisading nests and strands of cells are identified. Fibrous tissue is abundant in both, so

an adamantinoma can remain masked if biopsy is taken from a single lesion site.² Precaution must be taken to take samples from lytic as well as dense regions.

Following these principles, we took biopsy with a core biopsy needle. Histopathology was suggestive of fibrous dysplasia.




Figure 3: Showing trabeculae of woven bone with fibroblastic stroma and no osteoblastic rimming

VI. MANAGEMENT

Considering the facts that it was a benign lesion, the deformity had not progressed over the last 20 years, patient had no functional limitations or any significant limb length discrepancy, has had no pathological fracture and the lesion was involving almost the whole of tibia making a reconstruction difficult, we decided to keep the patient under observation. We would look for any change in her symptoms or an increase in the deformity and also get yearly X-rays and MRI to look for any enhancement of the lesion. Meanwhile, we started the patient on bisphosphonates and analgesics.

VII. DISCUSSION

Differentiation between fibrous dysplasia, osteofibrous dysplasia and adamantinoma is vital in such a case.

Fibrous dysplasia (FD) is a benign intramedullary fibro-osseous lesion where normal bone is replaced by fibrous tissue. It can involve a single bone (monostotic), a single limb (monomelic) or multiple bones (polyostotic). It is generally an incidental finding.³ Radiologically, the lesion is intramedullary, expansile and well-defined with an intact cortex. Although typically having a ground-glass appearance, it can also be completely lytic or sclerotic.⁴ Characteristic histologic findings indicative of fibrous dysplasia include fibrous stroma consisting of myxofibrous tissue and woven bone.

Osteofibrous dysplasia (OFD) is a bone-forming lesion in the ventral, intracortical area of the tibial shaft with histology different from fibrous dysplasia. Contrary to fibrous dysplasia, the formed, woven trabeculae in osteofibrous dysplasia are rimmed by cuboidal osteoblasts.⁵ There is a separate entity called OFD-like adamantinoma, which some believe to be a regressive

form of adamantinoma and others believe to be a precursor of adamantinoma.⁶

Adamantinoma is a primary low-grade malignant bone tumor most commonly seen involving the tibia. Histologically, adamantinoma shows a biphasic pattern of intermingled epithelial and osteofibrous components. Immunohistochemistry should be done to confirm the diagnosis.⁷

It is important to differentiate between the three entities to decide the further line of management. Fibrous dysplasia is a benign lesion, with rare incidences of malignant transformation, and the patient can be kept under observation.⁸ Osteofibrous dysplasia has been shown to carry a small but significant risk of containing co-existing adamantinoma or developing into adamantinoma, hence a wide resection of the lesion has been advocated by some.⁶ Adamantinoma is a slow-growing, malignant bone tumour and necessitates a wide extraperiosteal resection to prevent recurrence.⁹

REFERENCES RÉFÉRENCES REFERENCIAS

1. Mohan, Harsh & Mittal, Preeti & Mundi, Irneet & Kumar, Sudhir & Mohan, Correspondence. (2011). Fibrous dysplasia of bone: A clinicopathologic review. *Pathology and Laboratory Medicine International*. 3. 3-31. 10.2147/PLMI.S24866.
2. Ramanoudjame M, Guinebretière JM, Mascard E, Seringe R, Dimeglio A, Wicart P. Is there a link between osteofibrous dysplasia and adamantinoma? *Orthop Traumatol Surg Res*. 2011 Dec;97(8):877-80.
3. Anitha N, Sankari SL, Malathi L, Karthick R. Fibrous dysplasia-recent concepts. *J Pharm Bioallied Sci*. 2015; 7(Suppl 1):S171-S172.
4. Kushchayeva YS, Kushchayev SV, Glushko TY, et al. Fibrous dysplasia for radiologists: beyond ground glass bone matrix. *Insights Imaging*. 2018; 9(6):1035-1056.

5. Sakamoto A, Oda Y, Iwamoto Y, Tsuneyoshi M. A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to Gsalph mutation at the Arg201 codon: polymerase chain reaction-restriction fragment length polymorphism analysis of paraffin-embedded tissues. *J Mol Diagn.* 2000;2(2):67–72.
6. Lee R. S., Weitzel S., Eastwood D. M., Monsell F., Pringle J., Cannon S. R., Briggs T. W. R. Osteofibrous dysplasia of the tibia. *The Journal of Bone and Joint Surgery. British volume* 2006 88-B:5, 658-664.
7. Jain D, Jain VK, Vasishta RK, Ranjan P, Kumar Y. Adamantinoma: a clinicopathological review and update. *DiagnPathol.* 2008;3:8. Published 2008 Feb 15
8. Qu N, Yao W, Cui X, Zhang H. Malignant transformation in monostotic fibrous dysplasia: clinical features, imaging features, outcomes in 10 patients, and review. *Medicine (Baltimore).* 2015 Jan;94(3):e369.
9. Puchner SE, Varga R, Hobusch GM, Kasperek M, Panotopoulos J, Lang S, Windhager R, Funovics PT. Long-term outcome following treatment of Adamantinoma and Osteofibrous dysplasia of long bones. *Orthop Traumatol Surg Res.* 2016 Nov; 102(7):925-932.





This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: H
ORTHOPEDIC AND MUSCULOSKELETAL SYSTEM
Volume 20 Issue 1 Version 1.0 Year 2020
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Effectiveness of Perineural Dexmedetomidine and Ropivacaine on Preventing Phantom Limb Pain in Patients Undergoing Femoral Supracondylar Amputation

By MD. Ramírez-Jaime, MD. Estrada-Sara & MD. Martínez-Raquel

University of Guadalajara

Abstract- Background: Phantom limb pain is a frequent complication after limb amputation, its pathophysiology is complex and includes changes in the peripheral nerve, dorsal root ganglia, spinal cord, cerebral cortex, and thalamus. At this time, there is not an effective drug for treatment and prevention of phantom limb pain. Perineural local anesthetic infiltration has obtained different results in the prevention of phantom limb pain, so we propose to combine an α_2 agonist in peripheral nerve block to assess its effectiveness in preventing postoperative pain.

Keywords: *phantom limb pain, analgesia, dexmedetomidine, peripheral nerve block, supracondylar amputation.*

GJMR-H Classification: NLMC Code: WE 300



EFFECTIVENESS OF PERINEURAL DEXMEDETOMIDINE AND ROPIVACAINE ON PREVENTING PHANTOM LIMB PAIN IN PATIENTS UNDERGOING FEMORAL SUPRACONDYLAR AMPUTATION

Strictly as per the compliance and regulations of:



RESEARCH | DIVERSITY | ETHICS

Effectiveness of Perineural Dexmedetomidine and Ropivacaine on Preventing Phantom Limb Pain in Patients Undergoing Femoral Supracondylar Amputation

MD. Ramírez-Jaime ^α, MD. Estrada-Sara ^ο & MD. Martínez-Raquel ^ρ

Abstract- Background: Phantom limb pain is a frequent complication after limb amputation, its pathophysiology is complex and includes changes in the peripheral nerve, dorsal root ganglia, spinal cord, cerebral cortex, and thalamus. At this time, there is not an effective drug for treatment and prevention of phantom limb pain. Perineural local anesthetic infiltration has obtained different results in the prevention of phantom limb pain, so we propose to combine an $\alpha 2$ agonist in peripheral nerve block to assess its effectiveness in preventing postoperative pain.

Methods: This was a prospective, double-blind, controlled, and simple randomized study. We included 30 patients undergoing surgery for supracondylar femoral amputation, older than 18 years, ASA I-III, in a sample calculation of 95% in Confidence Interval and 80% of statistical power. We included 15 patients per group managed with subarachnoid neuraxial block, and a perineural infiltration before the sciatic nerve section with 10 ml of 0.5% ropivacaine + 50 mcg dexmedetomidine (RD Group), or 0.5% ropivacaine + 0.9% saline solution (Group RS), in both groups We continued a perineural infusion with 0.15% ropivacaine using an elastomeric pump for 24 hours; We evaluated stump pain and phantom limb pain, upon admission to recovery, 8 hrs, 24 hrs, 30 days and 3 months. The data analysis was carried out using the SPSS version 21 program; In all cases, we defined statistical significance when obtaining $p < 0.05$.

Results: This study included a total of 30 patients, 15 patients in the RD group and 15 patients in the RS group. Statistical significance was found in the pain levels of the stump at rest at 24 hours, being lower in the RD group ($p = 0.003$). This intervention also impacted the opioid requirements at 24 hours, requiring tramadol rescue 27% of the patients in the RD group, against 93% of the patients in the RS group ($p = 0.0002$). Regarding phantom limb pain, there was no incidence during the three months of follow-up in the RD group, against three patients who report mild phantom limb pain in the RS group.

Conclusions: The combination of ropivacaine with dexmedetomidine appears to be an effective intervention with minimal side effects to prevent the occurrence of acute and chronic pain as well as phantom limb pain in patients undergoing femoral supracondylar amputation as well as reducing the postoperative opioid requirements.

Keywords: phantom limb pain, analgesia, dexmedetomidine, peripheral nerve block, supracondylar amputation.

I. INTRODUCTION

Patients undergoing limb amputation surgery are at risk of postoperative pain. Phantom limb pain (PLP) is a painful sensation referred to the absent limb after amputation; but it's not limited to the extremities, phantom pain has also been reported after losing almost any body part, for example, nose, tongue or breast.¹

The onset time of PLP varies from days to years, but it's common to be experienced between the first 24 hours to one week after amputation.¹ In long-term studies, it's been observed a decrease in the frequency and duration of pain attacks over the years, which is accompanied by a decrement in its intensity, although in some cases, a worsening may occur.^{2,3,4}

a) Etiology and risk factors for PLP

Up to date, the exact reason that some patients develop PLP and others do not is unknown. It has been observed that its development is multifactorial, involving from peripheral, central and also psychological mechanisms.⁵ There is not a clear relationship between age or sex and the appearance of PLP in the literature, and it's more likely to appear when it's a bilateral amputation and how proximal it is.⁶

There are studies about the influence of previous pain on an extremity as a factor for the development of PLP.^{6,7,8} There are reports that more than 50% of patients described PLP as similar to the pain they suffered before amputation.^{9,10}

At our country, type 2 Diabetes is the most common pathology causing amputation, referred as vascular diseases, it contributes to 81% of cases. On the other hand, traumatic amputations represent 16%, tumors, and congenital diseases account for 3%.¹¹

b) Pathophysiology

We may assume that PLP is an example of neuropathic pain since it occurs mainly as a result of an attempt to reorganize the nervous system followed by

Author α σ ρ : Department of Anesthesiology of Guadalajara's Civil Hospital "Fray Antonio Alcalde". University of Guadalajara. Jalisco, México. e-mail: jarvil12@hotmail.com

the deference of all sensory information involving amputation with nerve section.

There are three mechanisms involved: "peripheral" given by the massive lesion discharge and the loss of nerve impulses towards the spinal cord.¹² "spinal" Experimental studies have provided evidence of structural, physiological and neurochemical changes in the deferential neurons of the medullary dorsal horn. And it also causes alterations in "central" processing like transneuronal changes at the level of the nucleus of the thalamus.^{1, 13}

There are many pharmacological therapies to treat PLP once it appears, and some others are trying to prevent it, without consistent results that allow us to have a standardized treatment regimen. *Madabhushi et al.* Made a case report of a patient undergoing femoral supracondylar amputation, using bupivacaine (local anesthetic) and clonidine (α_2 agonist) with excellent results, the patient didn't report any pain in the stump and neither PLP 12 months after surgery.¹⁴ There are also systematic reviews about the use of dexmedetomidine (α_2 agonist) as an adjuvant to the local anesthetic for neuraxial and peripheral nerve blocks, to prolong the duration of analgesia compared to local anesthetic only. Cataloging Dexmedetomidine as a potential adjuvant and with more favorable pharmacodynamic and safety profile than Clonidine.^{15,16}

Due the incidence of chronic pain or symptoms related to phantom limb, which may determine disability, a very poor quality of life by the dependence on consumption of opioid and non-opioid analgesics or neuropathic medications to decrease pain, we proposed preventive analgesia in this case, consisting in the application of an anesthetic and analgesic before the surgical incision of the sciatic nerve with the mainly aim to reduce the magnitude and duration of acute postoperative pain and so, assess the appearance or not of PLP, which it implies a decrease in morbidity and improvement in the quality of life; benefiting the patient, family and health institutions.

II. MATERIALS AND METHODS

We carried out this study in Guadalajara's Civil Hospital "Fray Antonio Alcalde", México. Our study was a controlled, simple randomized, double-blind, clinical trial, conducted within a period of one year, from January 2018 to January 2019.

Inclusion criteria: Adult patients, scheduled for femoral supracondylar amputation, being due to traumatic cause, chronic disease and malignant tumor. Neuraxial block as anesthetic technique. American Society of Anesthesiologists's physical status I-III. With signed informed consent.

The exclusion criteria were: Refusal of the patient to participate, allergies known to any of the medications used, chronic hepatopathy disease, chronic renal

disease, branch block or bradycardia and coagulation disorders.

Sample size calculation. We considered the total supracondylar amputations (110) performed at the Guadalajara's Civil Hospital during 2017, and established a significance level of 5% (0.05) and a statistical power of 80%. We obtained a total of 30 patients (15 per group).

RD Group. Perineural administration of 0.5% ropivacaine 10 ml adding dexmedetomidine 50 mcg, and maintenance with perineural catheter infusion connected to an elastomeric pump with 0.15% ropivacaine for 24 hours.

RS Group. Perineural administration of 0.5% ropivacaine 10 ml adding 0.5 ml saline solution 0.9%, and maintenance with perineural catheter infusion connected to an elastomeric pump with 0.15% ropivacaine for 24 hours.

Prior authorization by the Ethics and Research Committee of our Hospital, we assigned the patients in two groups randomly per sealed envelope.

Anxiolysis was given if required, with IV Midazolam 30 mcg/kg. Antibiotic prophylaxis with Cephalothin 1 gr IV. Preemptive analgesia with Paracetamol 1 gr IV. Subarachnoid neuraxial block was administered, using hyperbaric bupivacaine 30 mcg/kg and intraoperative analgesia Parecoxib 40 mg IV.

After dissection by the surgical team and before the section of the sciatic nerve, they identified the perineurium and infiltrated 10 ml of 0.5% ropivacaine + 50 mcg dexmedetomidine (RD Group) or 0.5% ropivacaine + 0.9% saline solution (0.5 ml). We asked the surgeon to wait 5 minutes before performing the sciatic nerve section. After the amputation of the pelvic limb and before the surgical team closed by planes, a perineural catheter (20 G) was placed and laterally exteriorized through a separate skin incision, connected to an elastomeric pump with 0.15% ropivacaine was placed in both groups for 24 hours.

We measured heart rate, blood pressure, sedation level (Ramsay Scale), at the end of the procedure, at PACU (Post-Anesthesia Care Unit), 8 hours, and up to 24 hours after. Also we recorded the pain in the stump, phantom pain using VAS (Visual Analogue Scale) in case of presenting at PACU, 8 hours, 24 hours, 30 days and up to 3 months after the surgery, all patients were followed by phone call after discharge from hospital. We recorded the rescue analgesia, and it was given with tramadol 1mg/kg when VAS > 4. We also monitored side and adverse effects associated with the use of dexmedetomidine such as bradycardia, hypotension, nausea, vomiting, and respiratory depression in PACU, 1 hour, 8, and 24 hours postoperatively.

We used the *Statistical Package for the Social Sciences version 21*¹⁷ for statistical analysis.

III. RESULTS

During January 2018 to January 2019, there were included 30 patients (15 per group) scheduled for supracondylar femoral amputation at our Hospital, under the anesthetic technique of subarachnoid block and perineural block of the sciatic nerve, which met the inclusion criteria from the study.

According to demographic data, of the 15 patients in the RD group were 2 women (13%) and 13 men (87%) with a mean age of 57.4 years (SD 20.7). We classified them according to physical status in ASA

I: 1 patient (7%), ASA II: 1 patient (7%), ASA 3: 13 patients (86%), with the following preoperative diagnoses: diabetes mellitus 60%, arterial occlusion 27%, cancer 7%, electric burn 7%.

Of the 15 patients in the RS group, were seven women (47%) and eight men (53%) with a mean age of 60 years (SD 17.4). We classified them according to physical status in ASA I: 2 patients (13%), ASA II: 1 patient (7%), ASA 3: 12 patients (80%), with the following diagnoses: diabetes mellitus 53%, arterial occlusion 33 %, cancer 7%, fracture exposed 7%. (Table 1).

Table 1: Demographic data

Variable	RD Group. Ropivacaína + Dexmedetomidina. N=15	RS Group. Ropivacaína + Solución Salina. N=15	P (CI 95%)
	(Mean ± SD)	(Mean ± SD)	
Edad	57.4 ± 20.7	60 ± 17.4	0.56
Género			
Masculino	13	8	
Femenino	2	7	
ASA			0.83
I	1	2	
II	1	1	
III	13	12	

Statistical significance when obtaining $P < 0.05$. Abbreviations: N (patients per group); ASA (Classification by the American Society of Anesthesiology); SD (Standard Deviation).


During the postoperative period, both groups were evaluated for pain intensity, both at rest and in movement, of the stump and phantom limb, from PACU, at 8 hours, 24 hours, 30 days, and up to 3 months.

Table 2: Pain Assessment (VAS) of the stump at rest and movement

Variables	Evaluated Period	RD Group N = 15	RS Group N = 15	p (CI 95%)
Pain Level		(Main ± SD)	(Main ± SD)	
Rest	PACU	0	0.13 ± 0.35	0.143
	8 hrs.	0.93 ± 0.59	1.2 ± 0.67	0.426
	24 hrs.	0.73 ± 0.59	1.60 ± 0.63	0.003
	30 days	0	0.33 ± 0.61	0.099
	3 months.	0	0.06 ± 0.25	0.303
Movement	PACU	0	0.20 ± 0.41	0.068
	8 hrs.	1.40 ± 0.73	1.60 ± 0.73	0.066
	24 hrs.	1.33 ± 0.48	1.73 ± 0.45	0.022
	30 days.	0	0.33 ± 0.72	0.189
	3 months.	0	0	-

Statistical significance when obtaining $P < 0.05$. Abbreviations: N (patients per group); VAS (Visual Analog Scale); DS (Standard Deviation); PACU (PostAnesthetic Care Unit) hrs (hours).

Graphic 1: Pain of stump at rest.



Abbreviations: RD (Ropivacaine + Dexmedetomidine), RS (Ropivacaine + Saline); PACU (PostAnesthetic Care Unit), Hrs (hours).

Pain values with VAS 4 and above, had the prescription of rescue with Tramadol at 1mg / kg. In the RD group, at 8 hours, five patients required Tramadol, at 24 hours four patients, and 48 hours 2 of them. In the RS group at 8 hours, nine patients were given tramadol


rescue, at 24 hours fourteen patients, and at 48 hours, 7 of them. Then it is possible to demonstrate with statistical significance that the perineural administration of dexmedetomidine does reduce the postoperative opioid requirements. (Table 3, Graph 2).

Table 3: Postoperative rescue with Tramadol

Variables	Evaluated period	RD Grup N = 15	RS Grup N = 15	p (CI 95%)
Tramadol rescue.		Percent.	Percent.	
	8 hrs.	33%	60%	0.143
	24 hrs.	27%	93%	0.0002
	48 hrs.	13%	47%	0.046

Statistical significance when obtaining $P < 0.05$. Abbreviations: hrs (hours).

Graphic 2. Postoperative Rescues with Tramadol.



Abbreviations: RD (Ropivacaine + Dexmedetomidine), RS (Ropivacaine + Saline Solution).

We evaluated the appearance of phantom limb pain at rest and movement, which was not reported by any patient of the RD group from the moment of evaluation at PACU up to 3 months of follow-up. It is worth mentioning that two patients of the RD group presented prior amputation, one by contralateral first toe, and another ipsilateral transtibial, none reported previous phantom limb pain.

From the RS group, up to 30 days, one patient reported mild phantom limb pain and one more patient moderate resting pain; on movement three patients reported mild pain at 30 days and only one patient mild pain at 3 months, who we referred to the Hospital Pain Clinic for evaluation and treatment. Without being these statistically significant values. (Table 4)

Table 4: Assessment of phantom limb pain at rest and movement

Variables	Evaluated period	RD Group N = 15 (Main \pm SD)	RS Group N = 15 (Main \pm SD)	p (CI 95%)
Pain Score				
Rest	PACU	0	0	-
	8 hrs.	0	0	-
	24 hrs.	0	0	-
	30 days.	0	0.20 \pm 0.56	0.343
	Three Months.	0	0.13 \pm 0.51	0.309
Movement	PACU	0	0	-
	8 hrs.	0	0	-
	24 hrs.	0	0	-
	30 days.	0	0.20 \pm 0.41	0.068
	Three months.	0	0.06 \pm 0.25	0.309

Statistical significance when obtaining $P < 0.05$. Abbreviations: N (patients per group); SD (Standard deviation), PACU (PostAnesthetic Care Unit) hrs (hours).

We decided to measure the possible side effects of perineurally administered medications on systemic blood pressure and heart rate in PACU, as well as the level of sedation (Ramsay scale) and oxygen saturation in PACU up to 24 hours after surgery.

We didn't find statistically significant differences in the values of systemic blood pressure, heart rate, and oxygen saturation after the intervention.

About sedation in the postoperative care unit, we found significant difference ($p < 0.025$) with a higher degree of sedation in the RD group with an average of 2.8 on the Ramsay scale. 2.4 in the RS group.


Table 5: Side effects on vitals and sedation after perineural block

Variables	Evaluated Period	RD Group N = 15 (Main \pm SD)	RS Group N = 15 (Main \pm SD)	p (CI 95%)
Mean arterial pressure (mmHg)	PACU	82.9 \pm 13.12	83.5 \pm 12.04	0.341
Heart rate (Bpm)	PACU	75.2 \pm 10.56	74.0 \pm 8.4	0.555
Pulse-oximetry (%)	PACU	96.4 \pm 2.02	95.7 \pm 1.90	0.552
	8 hrs.	94.93 \pm 0.96	95.33 \pm 0.72	0.261
	24 hrs.	94.86 \pm 0.80	95.06 \pm 0.59	0.057
Sedation (Ramsay)	PACU	2.80 \pm 0.41	2.40 \pm 0.50	0.025
	8 hrs.	2.20 \pm 0.41	2.00 \pm 0.41	0.068
	24 hrs.	2.00 \pm 0	2.00 \pm 0	-

Statistical significance when obtaining $P < 0.05$. Abbreviations: N (patients per group); SD(Standard deviation), PACU (PostAnesthetic Care Unit) hrs (hours).

Of the possible adverse effects of the drugs used in our study, dizziness, nausea, vomiting, headache, and blurred vision were evaluated the first 24 hours after the perineural block. It was observed mainly in the RD group, dizziness in 13% at 8 hours, against 7% in the RS group ($p = 0.068$). Nausea in 13% at 8 hours in both groups. And headache 13% in the RD group against 20% in the RS group at 8 hours ($p = 0.62$).

However, we didn't find statistically significant difference for any of the adverse effects measured.



Abbreviations: RD (Ropivacaine + Dexmedetomidine), RS (Ropivacaine + Saline); HRS (hours).

IV. DISCUSSION

This study yielded significant data regarding the analgesic intervention of perineural infiltration with the combination of a local anesthetic (Ropivacaine) and an α_2 agonist (Dexmedetomidine) since in the published literature there are only isolated reports of clinical cases of this combination, but no clinical trials and much less meta-analysis; there are some others of perineural infiltration with local anesthetic without additive for the prevention of PLP, and other about the addition of an α_2 agonist for prolongation of peripheral nerve block, without assessing the impact on the prevention of phantom limb pain after amputation objectively.

Regarding the levels of postoperative pain, at 24 hours lower scores of pain at rest were found using the combination ropivacaine + dexmedetomidine ($p = 0.003$); However, both interventions evaluated in this study with infiltration of local anesthetic and its postoperative infusion by using an elastomeric pump were effective for pain management, coinciding with the study by *Borgh* et al. In which they conclude that the use of a prolonged postoperative perineural perfusion of 0.5% ropivacaine is effective therapy for the treatment of phantom limb pain.¹⁸

Therefore, postoperative opioid consumption was also reduced as described by *Bosanquet* et al. in a systematic review and meta-analysis on the use of intraoperative placed perineural catheter with infusion of local postoperative anesthetic¹⁹. In this case, for our study, the addition of dexmedetomidine to perineural infiltration had a statistically significant difference in the reduction of the use of rescue tramadol at 24 hours,

compared with the use of only local anesthetic ($p = 0.0002$).

V. CONCLUSION

Phantom limb pain, associated with the amputation of a member of the organism, is a frequent complication after each procedure, sometimes reported with very high incidence rates.

In the understanding of the pathophysiology for the development of this neuropathic pain, there were proposed different interventions for its treatment, but few focused on preventing its onset. One of those proposals is perineural infiltration and continuous infusion of local anesthetic adding an adjuvant to mitigate peripheral sensitization in nociceptors at the medullary level and central de-centralization (cortex and thalamus) in a preventive manner, avoiding the development of the PLP, which once it appears is very complex to treat.

In this study, we corroborate and verified the advantages of doing a preventive intervention as described with a local anesthetic but adding an α_2 agonist, observing excellent results, and with no significant side effects.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Luo Y, Anderson T. Phantom Limb Pain: A review. *International Anesthesiology Clinics*. 2016. 54, Number 2, 121–139.

2. Jensen T, Krebs B, Rasmussen P. Immediate and long-term phantom limb pain in amputee: incidente, clinical characteristics and relationship to pre-amputation limb pain. *Pain* 1985; 21:267-78.
3. Dijkstra P, Geertzen H, Stewart R. Phantom pain and risk factors: A multivariate analysis. *J of Pain and Sym Manag* 2002; 24:578-585.
4. Ehde D, Czernieki J. Chronic phantom sensations, phantom pain, residual limb pain and other regional pain after lower limb amputation. *Arch Phys Med Rehabil*. 2000;81:1039-1044.
5. Weeks SR, Anderson-Barnes VC, Tsao JW. Phantom limb pain: theories and therapies. *Neurologist*. 2010; 16:277-286.
6. Davis R. Phantom sensation, phantom pain and stump pain. *Arch Phys Med Rehabil* 1993; 74:79-91.
7. Nikolajsen L, Corner K. The influence of preamputation pain on postamputation stump and phantom pain. *Pain* 1997; 72:393-405.
8. Katz J, Melzack R. Pain memories in phantom limbs: review and clinical observations. *Pain*. 1990; 43:319-333.
9. Jensen T, Krebs B, Rasmussen P. Immediate and long-term phantom limb pain in amputee: incidente, clinical characteristics and relationship to pre-amputation limb pain. *Pain* 1985; 21:267-78.
10. Jensen T, Krebs B, Nielsen J, Rasmussen P. Phantom limb, phantom pain and stump pain in amputees during the first 6 month following limb amputation. *Pain*. 1983; 17:243-56.
11. Vázquez E. Academia Nacional de Medicina. Los amputados, un reto para el Estado. Acta de la sesión del 4 de marzo del 2015.
12. Weinstein S. Phantom pain. *Oncology*. 1994; 8:65-70.
13. Nystrom B, Hagbarth KE. Microelectrode recordings from transected nerves in amputees with PLP. *Neurosci Lett*. 1981;27:211-216.
14. Madabhushi L, Reuben S. The efficacy of postoperative perineural infusion of bupivacaine and clonidine after lower extremity amputation in preventing phantom limb and stump pain. *Journal of Clinical Anesthesia*. 2007; 19, 226-229.
15. Abdallah F, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. *British Journal of Anaesthesia*. 2013. 110 (6): 915-25.
16. El-Boghdady, et. Al. Perineural dexmedetomidine is more effective than clonidine when added to local anesthetic for supraclavicular brachial plexus block: A systematic Review and meta-analysis. *Regional Anesthesia and Acute Pain Medicine*. 2017.124:6.
17. IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.
18. Borghi B, D'Addabbo M. The use of prolonged peripheral neural blockade after lower extremity amputation: the effect on symptoms associated with phantom limb syndrom. *Rev Anesthesia and Analgesia*. 2010; 111,5.
19. Bosanquet D, Glasbey J. Systematic review and meta-analysis of the efficacy of perineural local anaesthetic catheters after major lower limb amputation. *Eur J Vasc Endovasc Surg*. 2015; 50, 241-249.





This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: H
ORTHOPEDIC AND MUSCULOSKELETAL SYSTEM
Volume 20 Issue 1 Version 1.0 Year 2020
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

‘Arthrox’ an Advanced Ayurvedic Detox Program for Knee Osteoarthritis- A Case Report

By Smita Naram, Deepak S. Mahajan, Hemang Parekh & Ronak Naik

Ayushakti Ayurveda Pvt Ltd

Abstract- Reported case was a 68 years old Male with Early-stage Osteoarthritis of both knees (Sandhigata Vata), accompanied by reduced medial joint spaces bilaterally, marginal osteophytes. Initially, VAS scale rating was poor. Proven herbal formulations like Painmukti MJ, Painmukti Sandhical, Painmukti cream along with Advance Virechana (Arthrox), Knee Dhara, Yogbasti, and Matrabasti twice a week was given for 16 months. Visual analog scale for knee pain and an Ayurveda clinical assessment criteria used to evaluate the effects of Treatment and Herbal remedies monthly basis. After a treatment of 30 days of Advance Virechana (Arthrox), Knee Dhara and Yogbasti, Pain, movement, and stability of the joint was improved at an excellent level. During follow up visit with the help of Matrabasti twice a week, Pain, movement of joint and stability, and even X-ray reading were changed. In conclusion, this knee osteoarthritis patient's quality of life improved by Advance Virechana (Arthrox).

Keywords: osteoarthritis, arthrox, sandhigatvata, virechana.

GJMR-H Classification: NLMC Code: WE 348



Strictly as per the compliance and regulations of:



© 2020. Smita Naram, Deepak S. Mahajan, Hemang Parekh & Ronak Naik. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

'Arthrox' an Advanced Ayurvedic Detox Program for Knee Osteoarthritis- A Case Report

Smita Naram ^α, Deepak S. Mahajan ^σ, Hemang Parekh ^ρ & Ronak naik ^ω

Abstract- Reported case was a 68 years old Male with Early-stage Osteoarthritis of both knees (Sandhigata Vata), accompanied by reduced medial joint spaces bilaterally, marginal osteophytes. Initially, VAS scale rating was poor. Proven herbal formulations like Painmukti MJ, Painmukti Sandhical, Painmukti cream along with Advance Virechana (Arthrox), Knee Dhara, Yogbasti, and Matrabastitwice a week was given for 16months. Visual analog scale for knee pain and an Ayurveda clinical assessment criteria used to evaluate the effects of Treatment and Herbal remedies monthly basis. After a treatment of 30 days of Advance Virechana (Arthrox), Knee Dharaand Yogbasti, Pain, movement, and stability of the joint was improved at an excellent level. During follow up visit with the help of Matrabasti twice a week, Pain, movement of joint and stability, and even X-ray reading were change. In conclusion, this knee osteoarthritis patient's quality of life improved by Advance Virechana (Arthrox).

Keywords: osteoarthritis, arthrox, sandhigatvata, virechana.

I. BACKGROUND

Pain have been regarded as a symptom of an underlying condition.¹ Pain is the main causative factor that forces a person to visit a doctor immediately. The most common symptom as joint pain and stiffness is a diseased condition called Osteoarthritis. Initially, symptoms may occur only following exercise, but over time may become constant. Other symptoms may include joint swelling, decreased range of motion². Osteoarthritis is also erroneously called degenerative joint disease, which mostly affects cartilage. Cartilage is the slippery tissue that covers the ends of bones in a joint. Healthy cartilage allows bones to glide over each other, absorb the shock of movement. In osteoarthritis, the top layer of cartilage breaks down and wears away. This breakdown of cartilage allows bones under the cartilage to rub together. The rubbing causes pain, swelling, and loss of motion of the joint.³

The management of Osteoarthritis includes Lifestyle management, Physiotherapy, and Medication. The effectiveness of NSAIDs varies substantially. Paracetamol is clinically in effective in symptomatic the treatment of Osteoarthritis, nsoids such as naproxen, while more effective in severe cases, are associated with greater side effects, such as gastrointestinal bleeding.⁴ Another class of NSAIDs, COX-2 selective inhibitors

(such as celecoxib) are equally effective, and have lower rates of adverse gastrointestinal effects, but higher rates of cardiovascular disease such as myocardial infarction⁵. Because oral medication often does not lead to an adequate clinical response in OA, non-pharmacological therapies such as exercise, weight reduction, and physical therapies play role in the long-term management of osteoarthritis and are recommended. In addition, complementary and alternative medicine (CAM) treatments such as acupuncture or herbal medicines are used frequently by OA patients.

Acharya Charaka mentioned Sandhigatavata, which can be compare with Osteoarthritis. *Shula* (pain) is the cardinal feature of the disease associated with *Sandhishotha* (joint inflammation), *Vatapurna-dratisparsha* (edema palpable as air-filled sac), *Prasaraṇa-akuncanasavedana* (painful movement of the joints), and in the later stage *Hantisandhi* (restricted joint movements).⁶

II. CASE REPORT

Reported case was a 68 years old Male with Early-stage Osteoarthritis of both knees (Sandhigata Vata), accompanied by reduced medial joint spaces bilaterally, marginal osteophytes, Tibia spiking, and Patellar breaking. When the patient was 65 years old, they developed pain in the right knee, at the age of 65.6 years in the left knee. At the age of around 66 years, he had an X-ray with a diagnosis early-stage osteoarthritis. Therefore the patient took NSAIDs and received conservative treatment and Physiotherapy. However, knee pain increases progressively along with weight; on the other hand, his daily living activities stared decreasing with age. At the age of 68 years, this patient visited Ayushakti Ayurveda Pvt Ltd outdoor unit in Thane, Mumbai, Maharashtra, India branch with a complaint of both knee pain while walking and climbing. The patient got his self-reported visual analog scale (VAS) pain score in-between 8 and 9. On clinical examination, both knees showed mild detectable effusion. As per clinical symptoms and X-ray reporting patient diagnosed as having Osteoarthritis of both knee joints. The patient was convinced to undergo Advance Virechana (Arthrox), Knee Dhara, Yogbasti, and Herbal formulations for 20 days, followed by *matrabasti* (60 ml oil enema) twice a week for 12 months along with Herbal formulations. All the test drugs (table- 01) Pain Mukti MJ 400 mg twice a day after food, Pain Mukti Sandhical 720

Author ^{α σ ρ ω}: Ayushakti Ayurveda Pvt Ltd.
e-mail: drdeepakm@ayushakti.com

mg twice a day after food, Pain Mukti Cream for local Application were prepared by Ayushakti Ayurveda Pvt Ltd pharmacy, Plot number 78, Stice, Musalgaon, Sinnar, Nashik- 422112.

Table 1: Formulas for the test drug shown in table-01

Pain Mukti MJ		Pain Mukti Sandhical		Pain Mukti Cream	
Ingredients	Quantity	Ingredients	Quantity	Ingredients	Quantity
Nirgundi Ghan (Vitexnirgundo)	50 mg	Guggul (Commiphora mukul)	150mg	Mahanarayan oil	10%
Rasna Ghan (Pluchea lanceolata)	100mg	Asthishrunklaghan (Cissus quadrangularis)	100 mg	Lavang oil (Eugenia aromatica oil)	0.5 %
Shallaki Ghan (Boswelliaserrata)	100mg	Lajjalughana (Mimosa Pudica)	30 mg	Twak oil (Cinnamomum Zeylanicum oil)	0.5 %
Rakta Punarnava Ghan (Boerhaviadiffusa)	40mg	Lakha (Lacciferalacca)	20 mg	Pudinaphool (Menthaspicata)	5 %
Shunthi powder (Zinziberofficinalae)	25mg	Aswagandha (Withaniasominfera)	20 mg	Shuddha Guggul (Balsamodendron mukul)	1 %
Musta powder (Cyprus rotandus)	75mg	Mukta	400 mg	Marich ark (Capsicum extract)	0.1 %
				Gandhapurapo oil (Winter green oil)	10 %

The first regimen of Advance Virechana (Arthrox) was started for the patient after his informed written consent for the procedure, all the do's and don'ts, all the possible complications during Advance Virechana (Arthrox) procedure explained thoroughly.

III. TREATMENT PLAN ADVANCE VIRECHANA (ARTHROX)

The procedure of Advance Virechana (Arthrox) performed in three steps.

1. *Poorvakarma, ie. Preparatory procedures*- This was performed before therapy, which includes *Deepana* (Appetising drugs) and *Pachana* (Digestive drugs), which was then followed by *Snehapana*, ie. Oral administration of medicated ghee) for 4 days, planned after the examination of *Kostha* (nature of bowels) of the patient until achieving the symptoms of Adequate oleation (Internal consumption of medicated ghee). Simultaneously *Abhyanga* (external application of Oils) and *Swedana* (Steam) was given for five days.
2. *Pradhankarma, ie. Main procedure*- This was the actual administration of Advance Virechana (Arthrox) herbs, as per *Bala* (Strength) *Kostha* (nature

of bowels) of the patient. The herbal combination used was tablet virechana four tablets, manufactured by Ayushakti Ayurveda.

3. *Paschatkarma, ie. Post main procedure*- As per the number of bouts of bowel evacuated after giving Advance Virechana (Arthrox), *Sansarjanakrama* with *Mand*, *Peya*, and *Vilepee* advised for three days.

The assessment of Advance Virechana (Arthrox) based on various parameters termed as *Shuddhi* (cleansing) criteria like *Vaigiki* (number of bouts of stool passed), *Maniki* (quantitative measurements of stool), *Laingiki* (Symptoms), and *Antyaki* (assessment based on end points of purgation). This particular patient had *Madhyamshudhi*. In the second regimen, the Advance Virechana (Arthrox) procedure was followed by *Yogbastikrama* (8 enemas) and *Knee Dhara* (pouring of oil on knee anterior and posterior aspect) with *Mahanarayan oil* for eight days. All the test drugs Pain Mukti MJ 400 mg twice a day after food, Pain Mukti Sandhical 720 mg twice a day after food, Pain Mukti Cream for local Application was kept continue after that for 16 months. Matrabasti total of 60 ml (*Mahanarayan oil*-20 ml, *Balada oil*-20 ml, *Jivanyaghrut*-20 ml) twice a week advised for 16 months.

Table 2: Schedule of administration of treatment

Days	Treatment	Drug	Duration
1-5 days	Dry pindsweda	Shunthi powder (Zinziberofficinalae), Ajwain powder Trachispermum ammi	20 mins
6-10 days	Internal and external snehana (Oleation), Swedana (Steam)	Internal- Mahatiktaghruta External- Mahanarayan oil	20 mins
12 th day	Virechana (Detox)	Special virechana tablet	
13-15 days	Sansarjanakrama	Mand, Peya, Vilepee	
13-20 days	Yogbasti Knee dhara	Knee dhara- Mahanarayan oil	20 mins
Onwards	Matrabasti	(Mahanarayan oil-20 ml, Balada oil-20 ml, Jivanyaghrut -20 ml)	Twice a week

The overall improvement observed with symptoms like Pain (table-3), Swelling (table-4), Akunchana Prasarane Vedana (table-5) difficulty in

Walking (table-6) and difficulty in climbing (table-7) and were grades like following-

Table 3: Pain scale

Symptom	Grade
No Pain	0
Mild pain of bearable nature, comes occasionally	1
Moderate pain- Slight difficulty in joint movements due to pain , requires medication and may remain throughout the day	2
Severe Pain- More difficulty in moving the joints and disturbing sleep and requires strong analgesics	3

Table 4: Swelling scale

Symptom	Grade
No Swelling	0
Minimal edema only in joint Capsule	1
Edema in dependant parts	2
Massive edema in the limb	3

Table 5: Akunchana Prasaraane Vedana

Symptom	Grade
No Pain	0
Pain without wincing of face	1
Pain with wincing of face	2
Prevent complete flexion	3
Does not allow passive movement	4

Table 6: Difficulty in Walking

Symptom	Grade
No Effect	0
Needs Minimal Assistance / Can Stand or walk for 1 Hour	1
Needs Maximum Assistance / Can Stand or Work for less than 30 Minutes	2
Almost Not Standing or Walking or Bed Ridden	3

Table 7: Difficulty in climbing

Symptom	Grade
No Effect On Climbing	0
Needs Minimal Assistance	1
Needs Maximum Assistance	2
Almost No Climbing or Bed Ridden	3

IV. RESULTS

During the treatment of the first 30 days, patient experienced gradual improvement. All the symptoms were around 50 % reduced except climbing in first 30 days only (table-8). After the successful completion of all the arthrox treatment patient experienced 100 % relief in all the symptoms. His VAS scale reading was improved significantly. When the patient had his both knee X-ray after 13 months, it showed no abnormality except mildly reduced joint space in medial compartments of both knees (image-1 and image-2).

Table 8: Showing difference in symptoms in the first 30 days

Symptom	BT	AT	Relief in %
Pain scale	3	2	33.33333
Swelling	2	0	100
AkunchanaPrasaraneVedana	3	1	66.66667
Difficulty in Walking	2	1	50
Difficulty in climbing	2	2	0



Image 1: Before treatment



After treatment

V. DISCUSSION

Osteoarthritis (*Sandhigatvata*) is commonly known as wear and tear arthritis. In this natural cushion between the joints, cartilages wears away⁷. There may be inflammation in the joint spaces, which causes symptoms like Pain initially, later Swelling. Due to lack of this cushion and absorption material, inflammation, in *Sandhigatvata* the mobility of joints is restricted at the initial stage, and later it is aggravated by anatomical changes in the articular surfaces and joint capsule and the ligaments⁸. When the patient wants to move his knee

in his regular daily activities, he experiences the pain, which may cause wincing of the face. All the signs and symptoms noted for the patient, and the assessment was done. The symptoms assessed before starting treatment, after one month, three months, six months and final visit were after twelve months.

The two main events in any degenerative disease described by our Achary as are *Asthidhatukshyaya* and *Vataprakopa*, and according to Samhitas, *Vata* and *Asthi* have *Ashrayaashrayi-sambandh*(connection) in which the herbs are causing *Kshaya* of *Vata* are responsible for *Asthidhatuvridhhi* and vice versa⁹. Bastichikitsa is the best panchakarma treatment for vitiated *Vata*¹⁰. According to Acharya CharakPanchakarma procedure of Basti is called *Ardhchikitsa* (Half treatment) for *Vata*¹¹. *Virechana* increases the absorption of basti to achieve a target of pain relief in a short period. *Virechana* evacuates all morbid *Doshas* from all micro to macro *Dhatu* channels and regulates *Vata*, thus decreasing all symptoms of on *Srotasa* level¹². Painmukti MJ and Painmukti Sandhical are moderately effective and safe herb in chronic arthritic conditions along with painmukti cream for local application and used as an alternative to NSAID's without side effect¹³. *Cissusquadrangularis* present in Painmukti Sandhical can stimulate osteoblastogenesis¹⁴. *Boswelliaserrata* blocks an enzyme 5-lipoxygenase that plays a role in the formation of leukotrienes, which stimulates inflammation¹⁵.

VI. CONCLUSION

Arthrox plan can be used successfully in knee osteoarthritis for the long term; it can give better relief in Symptoms of Osteoarthritis as well as can reverse the early degenerative changes in X-ray readings.

REFERENCES RÉFÉRENCES REFERENCIAS

1. "International Association for the Study of Pain: Pain Definitions". Retrieved 12 January 2015. Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage Derived from The need of a taxonomy. Pain. 1979; 6(3):247–8. doi:10.1016/0304-3959(79)90046-0. PMID 460931.
2. "Osteoarthritis". National Institute of Arthritis and Musculoskeletal and Skin Diseases. April 2015. Retrieved 13 May 2015 https://en.wikipedia.org/wiki/Osteoarthritis#cite_note-NIH2015-1
3. P.K.Rai, Efficacy of leech therapy in the management of osteoarthritis (Sandhivata) IP: 182.57.131.202]
4. Flood J (March 2010). "The role of acetaminophen in the treatment of osteoarthritis". Am J Manag Care. 16 (Suppl Management): S48–54. PMID 20297877
5. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS (April 2008). "Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation". Health Technol Assess. 12 (11): 1–278, iii. PMID 18405470. doi:10.3310/hta12110.
6. Charaka Samhita with "Ayurveddipika" sanskrita commentary, Chikitsa 28/37, edited by Vaidya Yadavaji Trikamji Acharya, 2014, Chaukhambasurbharti Prakashana, Varanasi.
7. Osteoarthritis/ostearthritis-of-the-knee-degenerative-arthritis-of-the-knee#1<https://www.webmd.com/>
8. Perera PK, Parera M, Kumarsinghe N, "Effect of Sri Lankan traditional medicine and Aurveda on Sandhigatvata (Osteoarthritis of knee joint). Ayu 2014; 35:411-5.
9. Naram SP, Parekh H, Mahajan DS, Naik RD. A survey to evaluate the efficacy of virechana, basti and knee dhara in patients with Osteoarthritis of knee joint. Int J Res Med Sci2019;7:xxx-xx.
10. Agnivesh, Charaka Samhita; Pandit Kashinath Shasty & Dr. Gorakhnath Charurvedi, Vol-I, 25th Edition, Reprint 1995; Chaukhamba Bharati Academy, Varanasi; Pp. 1024, Pg. 468. (Ch. Su. 25/40).
11. Agnivesh, Charaka Samhita; Pandit Kashinath Shasty & Dr. Gorakhnath Charurvedi, Vol-II, 25th Edition, Reprint 2009; Chaukhamba Bharati Academy, Varanasi; Pp. 1208, Pg. 971. (Ch. Si. 1/39).
12. Naram SP, Parekh H, Mahajan DS, Naik RD. A survey to evaluate the efficacy of virechana, basti and knee dhara in patients with Osteoarthritis of knee joint. Int J Res Med Sci2019;7:xxx-xx.
13. Munshi Renuka Et Al: An Open, Randomized, Comparative Clinical Study To Assess The Analgesic & Anti-Inflammatory Efficacy Of PainmuktiMj Tablets, Painmukti Cream And Painmukti-Sandhical Tablets In Patients Suffering From Chronic Pain. International Ayurvedic Medical Journal {online} 2017 {cited June, 2017} Available from:http://www.iamj.in/posts/images/upload/1865_1876.pdf
14. Potu BK, Bhat KM, Rao MS, Nampurath GK, Chamallamudi MR, Nayak SR, Muttigi MS. Petroleum ether extract of *Cissusquadrangularis* (Linn.) enhances bone marrow mesenchymal stem cell proliferation and facilitates osteoblastogenesis. Clinics (Sao Paulo). 2009; 64(10):993-8.
15. an-ayurvedic-approach-to-osteoarthritis <https://www.integrativepractitioner.com/practice-management/news/>

GLOBAL JOURNALS GUIDELINES HANDBOOK 2020

WWW.GLOBALJOURNALS.ORG

MEMBERSHIPS

FELLOWS/ASSOCIATES OF MEDICAL RESEARCH COUNCIL

FMRC/AMRC MEMBERSHIPS

INTRODUCTION



FMRC/AMRC is the most prestigious membership of Global Journals accredited by Open Association of Research Society, U.S.A (OARS). The credentials of Fellow and Associate designations signify that the researcher has gained the knowledge of the fundamental and high-level concepts, and is a subject matter expert, proficient in an expertise course covering the professional code of conduct, and follows recognized standards of practice. The credentials are designated only to the researchers, scientists, and professionals that have been selected by a rigorous process by our Editorial Board and Management Board.

Associates of FMRC/AMRC are scientists and researchers from around the world are working on projects/researches that have huge potentials. Members support Global Journals' mission to advance technology for humanity and the profession.

FMRC

FELLOW OF MEDICAL RESEARCH COUNCIL

FELLOW OF MEDICAL RESEARCH COUNCIL is the most prestigious membership of Global Journals. It is an award and membership granted to individuals that the Open Association of Research Society judges to have made a 'substantial contribution to the improvement of computer science, technology, and electronics engineering.

The primary objective is to recognize the leaders in research and scientific fields of the current era with a global perspective and to create a channel between them and other researchers for better exposure and knowledge sharing. Members are most eminent scientists, engineers, and technologists from all across the world. Fellows are elected for life through a peer review process on the basis of excellence in the respective domain. There is no limit on the number of new nominations made in any year. Each year, the Open Association of Research Society elect up to 12 new Fellow Members.



BENEFIT

TO THE INSTITUTION

GET LETTER OF APPRECIATION

Global Journals sends a letter of appreciation of author to the Dean or CEO of the University or Company of which author is a part, signed by editor in chief or chief author.



EXCLUSIVE NETWORK

GET ACCESS TO A CLOSED NETWORK

A FMRC member gets access to a closed network of Tier 1 researchers and scientists with direct communication channel through our website. Fellows can reach out to other members or researchers directly. They should also be open to reaching out by other.

[Career](#)[Credibility](#)[Exclusive](#)[Reputation](#)

CERTIFICATE

CERTIFICATE, LOR AND LASER-MOMENTO

Fellows receive a printed copy of a certificate signed by our Chief Author that may be used for academic purposes and a personal recommendation letter to the dean of member's university.

[Career](#)[Credibility](#)[Exclusive](#)[Reputation](#)

DESIGNATION

GET HONORED TITLE OF MEMBERSHIP

Fellows can use the honored title of membership. The "FMRC" is an honored title which is accorded to a person's name viz. Dr. John E. Hall, Ph.D., FMRC or William Walldroff, M.S., FMRC.

[Career](#)[Credibility](#)[Exclusive](#)[Reputation](#)

RECOGNITION ON THE PLATFORM

BETTER VISIBILITY AND CITATION

All the Fellow members of FMRC get a badge of "Leading Member of Global Journals" on the Research Community that distinguishes them from others. Additionally, the profile is also partially maintained by our team for better visibility and citation. All fellows get a dedicated page on the website with their biography.

[Career](#)[Credibility](#)[Reputation](#)

FUTURE WORK

GET DISCOUNTS ON THE FUTURE PUBLICATIONS

Fellows receive discounts on the future publications with Global Journals up to 60%. Through our recommendation programs, members also receive discounts on publications made with OARS affiliated organizations.

Career

Financial



GJ INTERNAL ACCOUNT

UNLIMITED FORWARD OF EMAILS

Fellows get secure and fast GJ work emails with unlimited storage of emails that they may use them as their primary email. For example, john [AT] globaljournals [DOT] org.

Career

Credibility

Reputation



PREMIUM TOOLS

ACCESS TO ALL THE PREMIUM TOOLS

To take future researches to the zenith, fellows receive access to all the premium tools that Global Journals have to offer along with the partnership with some of the best marketing leading tools out there.

Financial

CONFERENCES & EVENTS

ORGANIZE SEMINAR/CONFERENCE

Fellows are authorized to organize symposium/seminar/conference on behalf of Global Journal Incorporation (USA). They can also participate in the same organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent. Additionally, they get free research conferences (and others) alerts.

Career

Credibility

Financial

EARLY INVITATIONS

EARLY INVITATIONS TO ALL THE SYMPOSIUMS, SEMINARS, CONFERENCES

All fellows receive the early invitations to all the symposiums, seminars, conferences and webinars hosted by Global Journals in their subject.

Exclusive





PUBLISHING ARTICLES & BOOKS

EARN 60% OF SALES PROCEEDS

Fellows can publish articles (limited) without any fees. Also, they can earn up to 70% of sales proceeds from the sale of reference/review books/literature/publishing of research paper. The FMRC member can decide its price and we can help in making the right decision.

Exclusive

Financial

REVIEWERS

GET A REMUNERATION OF 15% OF AUTHOR FEES

Fellow members are eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get a remuneration of 15% of author fees, taken from the author of a respective paper.

Financial

ACCESS TO EDITORIAL BOARD

BECOME A MEMBER OF THE EDITORIAL BOARD

Fellows and Associates may join as a member of the Editorial Board of Global Journals Incorporation (USA) after successful completion of three years as Fellow and as Peer Reviewer.

Career

Credibility

Exclusive

Reputation

AND MUCH MORE

GET ACCESS TO SCIENTIFIC MUSEUMS AND OBSERVATORIES ACROSS THE GLOBE

All members get access to 5 selected scientific museums and observatories across the globe. All researches published with Global Journals will be kept under deep archival facilities across regions for future protections and disaster recovery. They get 10 GB free secure cloud access for storing research files.

ASSOCIATE OF MEDICAL RESEARCH COUNCIL

ASSOCIATE OF MEDICAL RESEARCH COUNCIL is the membership of Global Journals awarded to individuals that the Open Association of Research Society judges to have made a 'substantial contribution to the improvement of computer science, technology, and electronics engineering.

The primary objective is to recognize the leaders in research and scientific fields of the current era with a global perspective and to create a channel between them and other researchers for better exposure and knowledge sharing. Members are most eminent scientists, engineers, and technologists from all across the world. Associate membership can later be promoted to Fellow Membership. Associates are elected for life through a peer review process on the basis of excellence in the respective domain. There is no limit on the number of new nominations made in any year. Each year, the Open Association of Research Society elect up to 12 new Associate Members.



BENEFIT

TO THE INSTITUTION

GET LETTER OF APPRECIATION

Global Journals sends a letter of appreciation of author to the Dean or CEO of the University or Company of which author is a part, signed by editor in chief or chief author.



EXCLUSIVE NETWORK

GET ACCESS TO A CLOSED NETWORK

A AMRC member gets access to a closed network of Tier 2 researchers and scientists with direct communication channel through our website. Associates can reach out to other members or researchers directly. They should also be open to reaching out by other.

Career

Credibility

Exclusive

Reputation



CERTIFICATE

CERTIFICATE, LOR AND LASER-MOMENTO

Associates receive a printed copy of a certificate signed by our Chief Author that may be used for academic purposes and a personal recommendation letter to the dean of member's university.

Career

Credibility

Exclusive

Reputation



DESIGNATION

GET HONORED TITLE OF MEMBERSHIP

Associates can use the honored title of membership. The "AMRC" is an honored title which is accorded to a person's name viz. Dr. John E. Hall, Ph.D., AMRC or William Walldroff, M.S., AMRC.

Career

Credibility

Exclusive

Reputation

RECOGNITION ON THE PLATFORM

BETTER VISIBILITY AND CITATION

All the Associate members of AMRC get a badge of "Leading Member of Global Journals" on the Research Community that distinguishes them from others. Additionally, the profile is also partially maintained by our team for better visibility and citation.

Career

Credibility

Reputation

FUTURE WORK

GET DISCOUNTS ON THE FUTURE PUBLICATIONS

Associates receive discounts on future publications with Global Journals up to 30%. Through our recommendation programs, members also receive discounts on publications made with OARS affiliated organizations.

Career

Financial



GJ ACCOUNT

UNLIMITED FORWARD OF EMAILS

Associates get secure and fast GJ work emails with 5GB forward of emails that they may use them as their primary email. For example, john [AT] globaljournals [DOT] org.

Career

Credibility

Reputation



PREMIUM TOOLS

ACCESS TO ALL THE PREMIUM TOOLS

To take future researches to the zenith, fellows receive access to almost all the premium tools that Global Journals have to offer along with the partnership with some of the best marketing leading tools out there.

Financial

CONFERENCES & EVENTS

ORGANIZE SEMINAR/CONFERENCE

Associates are authorized to organize symposium/seminar/conference on behalf of Global Journal Incorporation (USA). They can also participate in the same organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent. Additionally, they get free research conferences (and others) alerts.

Career

Credibility

Financial

EARLY INVITATIONS

EARLY INVITATIONS TO ALL THE SYMPOSIUMS, SEMINARS, CONFERENCES

All associates receive the early invitations to all the symposiums, seminars, conferences and webinars hosted by Global Journals in their subject.

Exclusive



PUBLISHING ARTICLES & BOOKS

EARN 60% OF SALES PROCEEDS

Associates can publish articles (limited) without any fees. Also, they can earn up to 30-40% of sales proceeds from the sale of reference/review books/literature/publishing of research paper

Exclusive

Financial

REVIEWERS

GET A REMUNERATION OF 15% OF AUTHOR FEES


Associate members are eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get a remuneration of 15% of author fees, taken from the author of a respective paper.

Financial

AND MUCH MORE

GET ACCESS TO SCIENTIFIC MUSEUMS AND OBSERVATORIES ACROSS THE GLOBE

All members get access to 2 selected scientific museums and observatories across the globe. All researches published with Global Journals will be kept under deep archival facilities across regions for future protections and disaster recovery. They get 5 GB free secure cloud access for storing research files.



ASSOCIATE	FELLOW	RESEARCH GROUP	BASIC
\$4800 lifetime designation	\$6800 lifetime designation	\$12500.00 organizational	APC per article
Certificate , LoR and Momento 2 discounted publishing/year Gradation of Research 10 research contacts/day 1 GB Cloud Storage GJ Community Access	Certificate , LoR and Momento Unlimited discounted publishing/year Gradation of Research Unlimited research contacts/day 5 GB Cloud Storage Online Presense Assistance GJ Community Access	Certificates , LoRs and Momentos Unlimited free publishing/year Gradation of Research Unlimited research contacts/day Unlimited Cloud Storage Online Presense Assistance GJ Community Access	GJ Community Access



PREFERRED AUTHOR GUIDELINES

We accept the manuscript submissions in any standard (generic) format.

We typeset manuscripts using advanced typesetting tools like Adobe In Design, CorelDraw, TeXnicCenter, and TeXStudio. We usually recommend authors submit their research using any standard format they are comfortable with, and let Global Journals do the rest.

Alternatively, you can download our basic template from <https://globaljournals.org/Template>

Authors should submit their complete paper/article, including text illustrations, graphics, conclusions, artwork, and tables. Authors who are not able to submit manuscript using the form above can email the manuscript department at submit@globaljournals.org or get in touch with chiefeditor@globaljournals.org if they wish to send the abstract before submission.

BEFORE AND DURING SUBMISSION

Authors must ensure the information provided during the submission of a paper is authentic. Please go through the following checklist before submitting:

1. Authors must go through the complete author guideline and understand and *agree to Global Journals' ethics and code of conduct*, along with author responsibilities.
2. Authors must accept the privacy policy, terms, and conditions of Global Journals.
3. Ensure corresponding author's email address and postal address are accurate and reachable.
4. Manuscript to be submitted must include keywords, an abstract, a paper title, co-author(s') names and details (email address, name, phone number, and institution), figures and illustrations in vector format including appropriate captions, tables, including titles and footnotes, a conclusion, results, acknowledgments and references.
5. Authors should submit paper in a ZIP archive if any supplementary files are required along with the paper.
6. Proper permissions must be acquired for the use of any copyrighted material.
7. Manuscript submitted *must not have been submitted or published elsewhere* and all authors must be aware of the submission.

Declaration of Conflicts of Interest

It is required for authors to declare all financial, institutional, and personal relationships with other individuals and organizations that could influence (bias) their research.

POLICY ON PLAGIARISM

Plagiarism is not acceptable in Global Journals submissions at all.

Plagiarized content will not be considered for publication. We reserve the right to inform authors' institutions about plagiarism detected either before or after publication. If plagiarism is identified, we will follow COPE guidelines:

Authors are solely responsible for all the plagiarism that is found. The author must not fabricate, falsify or plagiarize existing research data. The following, if copied, will be considered plagiarism:

- Words (language)
- Ideas
- Findings
- Writings
- Diagrams
- Graphs
- Illustrations
- Lectures



- Printed material
- Graphic representations
- Computer programs
- Electronic material
- Any other original work

AUTHORSHIP POLICIES

Global Journals follows the definition of authorship set up by the Open Association of Research Society, USA. According to its guidelines, authorship criteria must be based on:

1. Substantial contributions to the conception and acquisition of data, analysis, and interpretation of findings.
2. Drafting the paper and revising it critically regarding important academic content.
3. Final approval of the version of the paper to be published.

Changes in Authorship

The corresponding author should mention the name and complete details of all co-authors during submission and in manuscript. We support addition, rearrangement, manipulation, and deletions in authors list till the early view publication of the journal. We expect that corresponding author will notify all co-authors of submission. We follow COPE guidelines for changes in authorship.

Copyright

During submission of the manuscript, the author is confirming an exclusive license agreement with Global Journals which gives Global Journals the authority to reproduce, reuse, and republish authors' research. We also believe in flexible copyright terms where copyright may remain with authors/employers/institutions as well. Contact your editor after acceptance to choose your copyright policy. You may follow this form for copyright transfers.

Appealing Decisions

Unless specified in the notification, the Editorial Board's decision on publication of the paper is final and cannot be appealed before making the major change in the manuscript.

Acknowledgments

Contributors to the research other than authors credited should be mentioned in Acknowledgments. The source of funding for the research can be included. Suppliers of resources may be mentioned along with their addresses.

Declaration of funding sources

Global Journals is in partnership with various universities, laboratories, and other institutions worldwide in the research domain. Authors are requested to disclose their source of funding during every stage of their research, such as making analysis, performing laboratory operations, computing data, and using institutional resources, from writing an article to its submission. This will also help authors to get reimbursements by requesting an open access publication letter from Global Journals and submitting to the respective funding source.

PREPARING YOUR MANUSCRIPT

Authors can submit papers and articles in an acceptable file format: MS Word (doc, docx), LaTeX (.tex, .zip or .rar including all of your files), Adobe PDF (.pdf), rich text format (.rtf), simple text document (.txt), Open Document Text (.odt), and Apple Pages (.pages). Our professional layout editors will format the entire paper according to our official guidelines. This is one of the highlights of publishing with Global Journals—authors should not be concerned about the formatting of their paper. Global Journals accepts articles and manuscripts in every major language, be it Spanish, Chinese, Japanese, Portuguese, Russian, French, German, Dutch, Italian, Greek, or any other national language, but the title, subtitle, and abstract should be in English. This will facilitate indexing and the pre-peer review process.

The following is the official style and template developed for publication of a research paper. Authors are not required to follow this style during the submission of the paper. It is just for reference purposes.



Manuscript Style Instruction (Optional)

- Microsoft Word Document Setting Instructions.
- Font type of all text should be Swis721 Lt BT.
- Page size: 8.27" x 11", left margin: 0.65, right margin: 0.65, bottom margin: 0.75.
- Paper title should be in one column of font size 24.
- Author name in font size of 11 in one column.
- Abstract: font size 9 with the word "Abstract" in bold italics.
- Main text: font size 10 with two justified columns.
- Two columns with equal column width of 3.38 and spacing of 0.2.
- First character must be three lines drop-capped.
- The paragraph before spacing of 1 pt and after of 0 pt.
- Line spacing of 1 pt.
- Large images must be in one column.
- The names of first main headings (Heading 1) must be in Roman font, capital letters, and font size of 10.
- The names of second main headings (Heading 2) must not include numbers and must be in italics with a font size of 10.

Structure and Format of Manuscript

The recommended size of an original research paper is under 15,000 words and review papers under 7,000 words. Research articles should be less than 10,000 words. Research papers are usually longer than review papers. Review papers are reports of significant research (typically less than 7,000 words, including tables, figures, and references)

A research paper must include:

- a) A title which should be relevant to the theme of the paper.
- b) A summary, known as an abstract (less than 150 words), containing the major results and conclusions.
- c) Up to 10 keywords that precisely identify the paper's subject, purpose, and focus.
- d) An introduction, giving fundamental background objectives.
- e) Resources and techniques with sufficient complete experimental details (wherever possible by reference) to permit repetition, sources of information must be given, and numerical methods must be specified by reference.
- f) Results which should be presented concisely by well-designed tables and figures.
- g) Suitable statistical data should also be given.
- h) All data must have been gathered with attention to numerical detail in the planning stage.

Design has been recognized to be essential to experiments for a considerable time, and the editor has decided that any paper that appears not to have adequate numerical treatments of the data will be returned unrefereed.

- i) Discussion should cover implications and consequences and not just recapitulate the results; conclusions should also be summarized.
- j) There should be brief acknowledgments.
- k) There ought to be references in the conventional format. Global Journals recommends APA format.

Authors should carefully consider the preparation of papers to ensure that they communicate effectively. Papers are much more likely to be accepted if they are carefully designed and laid out, contain few or no errors, are summarizing, and follow instructions. They will also be published with much fewer delays than those that require much technical and editorial correction.

The Editorial Board reserves the right to make literary corrections and suggestions to improve brevity.



FORMAT STRUCTURE

It is necessary that authors take care in submitting a manuscript that is written in simple language and adheres to published guidelines.

All manuscripts submitted to Global Journals should include:

Title

The title page must carry an informative title that reflects the content, a running title (less than 45 characters together with spaces), names of the authors and co-authors, and the place(s) where the work was carried out.

Author details

The full postal address of any related author(s) must be specified.

Abstract

The abstract is the foundation of the research paper. It should be clear and concise and must contain the objective of the paper and inferences drawn. It is advised to not include big mathematical equations or complicated jargon.

Many researchers searching for information online will use search engines such as Google, Yahoo or others. By optimizing your paper for search engines, you will amplify the chance of someone finding it. In turn, this will make it more likely to be viewed and cited in further works. Global Journals has compiled these guidelines to facilitate you to maximize the web-friendliness of the most public part of your paper.

Keywords

A major lynchpin of research work for the writing of research papers is the keyword search, which one will employ to find both library and internet resources. Up to eleven keywords or very brief phrases have to be given to help data retrieval, mining, and indexing.

One must be persistent and creative in using keywords. An effective keyword search requires a strategy: planning of a list of possible keywords and phrases to try.

Choice of the main keywords is the first tool of writing a research paper. Research paper writing is an art. Keyword search should be as strategic as possible.

One should start brainstorming lists of potential keywords before even beginning searching. Think about the most important concepts related to research work. Ask, "What words would a source have to include to be truly valuable in a research paper?" Then consider synonyms for the important words.

It may take the discovery of only one important paper to steer in the right keyword direction because, in most databases, the keywords under which a research paper is abstracted are listed with the paper.

Numerical Methods

Numerical methods used should be transparent and, where appropriate, supported by references.

Abbreviations

Authors must list all the abbreviations used in the paper at the end of the paper or in a separate table before using them.

Formulas and equations

Authors are advised to submit any mathematical equation using either MathJax, KaTeX, or LaTeX, or in a very high-quality image.

Tables, Figures, and Figure Legends

Tables: Tables should be cautiously designed, uncrowned, and include only essential data. Each must have an Arabic number, e.g., Table 4, a self-explanatory caption, and be on a separate sheet. Authors must submit tables in an editable format and not as images. References to these tables (if any) must be mentioned accurately.



Figures

Figures are supposed to be submitted as separate files. Always include a citation in the text for each figure using Arabic numbers, e.g., Fig. 4. Artwork must be submitted online in vector electronic form or by emailing it.

PREPARATION OF ELETRONIC FIGURES FOR PUBLICATION

Although low-quality images are sufficient for review purposes, print publication requires high-quality images to prevent the final product being blurred or fuzzy. Submit (possibly by e-mail) EPS (line art) or TIFF (halftone/ photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Avoid using pixel-oriented software. Scans (TIFF only) should have a resolution of at least 350 dpi (halftone) or 700 to 1100 dpi (line drawings). Please give the data for figures in black and white or submit a Color Work Agreement form. EPS files must be saved with fonts embedded (and with a TIFF preview, if possible).

For scanned images, the scanning resolution at final image size ought to be as follows to ensure good reproduction: line art: >650 dpi; halftones (including gel photographs): >350 dpi; figures containing both halftone and line images: >650 dpi.

Color charges: Authors are advised to pay the full cost for the reproduction of their color artwork. Hence, please note that if there is color artwork in your manuscript when it is accepted for publication, we would require you to complete and return a Color Work Agreement form before your paper can be published. Also, you can email your editor to remove the color fee after acceptance of the paper.

TIPS FOR WRITING A GOOD QUALITY MEDICAL RESEARCH PAPER

1. Choosing the topic: In most cases, the topic is selected by the interests of the author, but it can also be suggested by the guides. You can have several topics, and then judge which you are most comfortable with. This may be done by asking several questions of yourself, like "Will I be able to carry out a search in this area? Will I find all necessary resources to accomplish the search? Will I be able to find all information in this field area?" If the answer to this type of question is "yes," then you ought to choose that topic. In most cases, you may have to conduct surveys and visit several places. Also, you might have to do a lot of work to find all the rises and falls of the various data on that subject. Sometimes, detailed information plays a vital role, instead of short information. Evaluators are human: The first thing to remember is that evaluators are also human beings. They are not only meant for rejecting a paper. They are here to evaluate your paper. So present your best aspect.

2. Think like evaluators: If you are in confusion or getting demotivated because your paper may not be accepted by the evaluators, then think, and try to evaluate your paper like an evaluator. Try to understand what an evaluator wants in your research paper, and you will automatically have your answer. Make blueprints of paper: The outline is the plan or framework that will help you to arrange your thoughts. It will make your paper logical. But remember that all points of your outline must be related to the topic you have chosen.

3. Ask your guides: If you are having any difficulty with your research, then do not hesitate to share your difficulty with your guide (if you have one). They will surely help you out and resolve your doubts. If you can't clarify what exactly you require for your work, then ask your supervisor to help you with an alternative. He or she might also provide you with a list of essential readings.

4. Use of computer is recommended: As you are doing research in the field of medical research then this point is quite obvious. Use right software: Always use good quality software packages. If you are not capable of judging good software, then you can lose the quality of your paper unknowingly. There are various programs available to help you which you can get through the internet.

5. Use the internet for help: An excellent start for your paper is using Google. It is a wondrous search engine, where you can have your doubts resolved. You may also read some answers for the frequent question of how to write your research paper or find a model research paper. You can download books from the internet. If you have all the required books, place importance on reading, selecting, and analyzing the specified information. Then sketch out your research paper. Use big pictures: You may use encyclopedias like Wikipedia to get pictures with the best resolution. At Global Journals, you should strictly follow here.



6. Bookmarks are useful: When you read any book or magazine, you generally use bookmarks, right? It is a good habit which helps to not lose your continuity. You should always use bookmarks while searching on the internet also, which will make your search easier.

7. Revise what you wrote: When you write anything, always read it, summarize it, and then finalize it.

8. Make every effort: Make every effort to mention what you are going to write in your paper. That means always have a good start. Try to mention everything in the introduction—what is the need for a particular research paper. Polish your work with good writing skills and always give an evaluator what he wants. Make backups: When you are going to do any important thing like making a research paper, you should always have backup copies of it either on your computer or on paper. This protects you from losing any portion of your important data.

9. Produce good diagrams of your own: Always try to include good charts or diagrams in your paper to improve quality. Using several unnecessary diagrams will degrade the quality of your paper by creating a hodgepodge. So always try to include diagrams which were made by you to improve the readability of your paper. Use of direct quotes: When you do research relevant to literature, history, or current affairs, then use of quotes becomes essential, but if the study is relevant to science, use of quotes is not preferable.

10. Use proper verb tense: Use proper verb tenses in your paper. Use past tense to present those events that have happened. Use present tense to indicate events that are going on. Use future tense to indicate events that will happen in the future. Use of wrong tenses will confuse the evaluator. Avoid sentences that are incomplete.

11. Pick a good study spot: Always try to pick a spot for your research which is quiet. Not every spot is good for studying.

12. Know what you know: Always try to know what you know by making objectives, otherwise you will be confused and unable to achieve your target.

13. Use good grammar: Always use good grammar and words that will have a positive impact on the evaluator; use of good vocabulary does not mean using tough words which the evaluator has to find in a dictionary. Do not fragment sentences. Eliminate one-word sentences. Do not ever use a big word when a smaller one would suffice.

Verbs have to be in agreement with their subjects. In a research paper, do not start sentences with conjunctions or finish them with prepositions. When writing formally, it is advisable to never split an infinitive because someone will (wrongly) complain. Avoid clichés like a disease. Always shun irritating alliteration. Use language which is simple and straightforward. Put together a neat summary.

14. Arrangement of information: Each section of the main body should start with an opening sentence, and there should be a changeover at the end of the section. Give only valid and powerful arguments for your topic. You may also maintain your arguments with records.

15. Never start at the last minute: Always allow enough time for research work. Leaving everything to the last minute will degrade your paper and spoil your work.

16. Multitasking in research is not good: Doing several things at the same time is a bad habit in the case of research activity. Research is an area where everything has a particular time slot. Divide your research work into parts, and do a particular part in a particular time slot.

17. Never copy others' work: Never copy others' work and give it your name because if the evaluator has seen it anywhere, you will be in trouble. Take proper rest and food: No matter how many hours you spend on your research activity, if you are not taking care of your health, then all your efforts will have been in vain. For quality research, take proper rest and food.

18. Go to seminars: Attend seminars if the topic is relevant to your research area. Utilize all your resources.

19. Refresh your mind after intervals: Try to give your mind a rest by listening to soft music or sleeping in intervals. This will also improve your memory. Acquire colleagues: Always try to acquire colleagues. No matter how sharp you are, if you acquire colleagues, they can give you ideas which will be helpful to your research.



20. Think technically: Always think technically. If anything happens, search for its reasons, benefits, and demerits. Think and then print: When you go to print your paper, check that tables are not split, headings are not detached from their descriptions, and page sequence is maintained.

21. Adding unnecessary information: Do not add unnecessary information like "I have used MS Excel to draw graphs." Irrelevant and inappropriate material is superfluous. Foreign terminology and phrases are not apropos. One should never take a broad view. Analogy is like feathers on a snake. Use words properly, regardless of how others use them. Remove quotations. Puns are for kids, not grunt readers. Never oversimplify: When adding material to your research paper, never go for oversimplification; this will definitely irritate the evaluator. Be specific. Never use rhythmic redundancies. Contractions shouldn't be used in a research paper. Comparisons are as terrible as clichés. Give up ampersands, abbreviations, and so on. Remove commas that are not necessary. Parenthetical words should be between brackets or commas. Understatement is always the best way to put forward earth-shaking thoughts. Give a detailed literary review.

22. Report concluded results: Use concluded results. From raw data, filter the results, and then conclude your studies based on measurements and observations taken. An appropriate number of decimal places should be used. Parenthetical remarks are prohibited here. Proofread carefully at the final stage. At the end, give an outline to your arguments. Spot perspectives of further study of the subject. Justify your conclusion at the bottom sufficiently, which will probably include examples.

23. Upon conclusion: Once you have concluded your research, the next most important step is to present your findings. Presentation is extremely important as it is the definite medium through which your research is going to be in print for the rest of the crowd. Care should be taken to categorize your thoughts well and present them in a logical and neat manner. A good quality research paper format is essential because it serves to highlight your research paper and bring to light all necessary aspects of your research.

INFORMAL GUIDELINES OF RESEARCH PAPER WRITING

Key points to remember:

- Submit all work in its final form.
- Write your paper in the form which is presented in the guidelines using the template.
- Please note the criteria peer reviewers will use for grading the final paper.

Final points:

One purpose of organizing a research paper is to let people interpret your efforts selectively. The journal requires the following sections, submitted in the order listed, with each section starting on a new page:

The introduction: This will be compiled from reference matter and reflect the design processes or outline of basis that directed you to make a study. As you carry out the process of study, the method and process section will be constructed like that. The results segment will show related statistics in nearly sequential order and direct reviewers to similar intellectual paths throughout the data that you gathered to carry out your study.

The discussion section:

This will provide understanding of the data and projections as to the implications of the results. The use of good quality references throughout the paper will give the effort trustworthiness by representing an alertness to prior workings.

Writing a research paper is not an easy job, no matter how trouble-free the actual research or concept. Practice, excellent preparation, and controlled record-keeping are the only means to make straightforward progression.

General style:

Specific editorial column necessities for compliance of a manuscript will always take over from directions in these general guidelines.

To make a paper clear: Adhere to recommended page limits.



Mistakes to avoid:

- Insertion of a title at the foot of a page with subsequent text on the next page.
- Separating a table, chart, or figure—confine each to a single page.
- Submitting a manuscript with pages out of sequence.
- In every section of your document, use standard writing style, including articles ("a" and "the").
- Keep paying attention to the topic of the paper.
- Use paragraphs to split each significant point (excluding the abstract).
- Align the primary line of each section.
- Present your points in sound order.
- Use present tense to report well-accepted matters.
- Use past tense to describe specific results.
- Do not use familiar wording; don't address the reviewer directly. Don't use slang or superlatives.
- Avoid use of extra pictures—include only those figures essential to presenting results.

Title page:

Choose a revealing title. It should be short and include the name(s) and address(es) of all authors. It should not have acronyms or abbreviations or exceed two printed lines.

Abstract: This summary should be two hundred words or less. It should clearly and briefly explain the key findings reported in the manuscript and must have precise statistics. It should not have acronyms or abbreviations. It should be logical in itself. Do not cite references at this point.

An abstract is a brief, distinct paragraph summary of finished work or work in development. In a minute or less, a reviewer can be taught the foundation behind the study, common approaches to the problem, relevant results, and significant conclusions or new questions.

Write your summary when your paper is completed because how can you write the summary of anything which is not yet written? Wealth of terminology is very essential in abstract. Use comprehensive sentences, and do not sacrifice readability for brevity; you can maintain it succinctly by phrasing sentences so that they provide more than a lone rationale. The author can at this moment go straight to shortening the outcome. Sum up the study with the subsequent elements in any summary. Try to limit the initial two items to no more than one line each.

Reason for writing the article—theory, overall issue, purpose.

- Fundamental goal.
- To-the-point depiction of the research.
- Consequences, including definite statistics—if the consequences are quantitative in nature, account for this; results of any numerical analysis should be reported. Significant conclusions or questions that emerge from the research.

Approach:

- Single section and succinct.
- An outline of the job done is always written in past tense.
- Concentrate on shortening results—limit background information to a verdict or two.
- Exact spelling, clarity of sentences and phrases, and appropriate reporting of quantities (proper units, important statistics) are just as significant in an abstract as they are anywhere else.

Introduction:

The introduction should "introduce" the manuscript. The reviewer should be presented with sufficient background information to be capable of comprehending and calculating the purpose of your study without having to refer to other works. The basis for the study should be offered. Give the most important references, but avoid making a comprehensive appraisal of the topic. Describe the problem visibly. If the problem is not acknowledged in a logical, reasonable way, the reviewer will give no attention to your results. Speak in common terms about techniques used to explain the problem, if needed, but do not present any particulars about the protocols here.



The following approach can create a valuable beginning:

- Explain the value (significance) of the study.
- Defend the model—why did you employ this particular system or method? What is its compensation? Remark upon its appropriateness from an abstract point of view as well as pointing out sensible reasons for using it.
- Present a justification. State your particular theory(-ies) or aim(s), and describe the logic that led you to choose them.
- Briefly explain the study's tentative purpose and how it meets the declared objectives.

Approach:

Use past tense except for when referring to recognized facts. After all, the manuscript will be submitted after the entire job is done. Sort out your thoughts; manufacture one key point for every section. If you make the four points listed above, you will need at least four paragraphs. Present surrounding information only when it is necessary to support a situation. The reviewer does not desire to read everything you know about a topic. Shape the theory specifically—do not take a broad view.

As always, give awareness to spelling, simplicity, and correctness of sentences and phrases.

Procedures (methods and materials):

This part is supposed to be the easiest to carve if you have good skills. A soundly written procedures segment allows a capable scientist to replicate your results. Present precise information about your supplies. The suppliers and clarity of reagents can be helpful bits of information. Present methods in sequential order, but linked methodologies can be grouped as a segment. Be concise when relating the protocols. Attempt to give the least amount of information that would permit another capable scientist to replicate your outcome, but be cautious that vital information is integrated. The use of subheadings is suggested and ought to be synchronized with the results section.

When a technique is used that has been well-described in another section, mention the specific item describing the way, but draw the basic principle while stating the situation. The purpose is to show all particular resources and broad procedures so that another person may use some or all of the methods in one more study or referee the scientific value of your work. It is not to be a step-by-step report of the whole thing you did, nor is a methods section a set of orders.

Materials:

Materials may be reported in part of a section or else they may be recognized along with your measures.

Methods:

- Report the method and not the particulars of each process that engaged the same methodology.
- Describe the method entirely.
- To be succinct, present methods under headings dedicated to specific dealings or groups of measures.
- Simplify—detail how procedures were completed, not how they were performed on a particular day.
- If well-known procedures were used, account for the procedure by name, possibly with a reference, and that's all.

Approach:

It is embarrassing to use vigorous voice when documenting methods without using first person, which would focus the reviewer's interest on the researcher rather than the job. As a result, when writing up the methods, most authors use third person passive voice.

Use standard style in this and every other part of the paper—avoid familiar lists, and use full sentences.

What to keep away from:

- Resources and methods are not a set of information.
- Skip all descriptive information and surroundings—save it for the argument.
- Leave out information that is immaterial to a third party.



Results:

The principle of a results segment is to present and demonstrate your conclusion. Create this part as entirely objective details of the outcome, and save all understanding for the discussion.

The page length of this segment is set by the sum and types of data to be reported. Use statistics and tables, if suitable, to present consequences most efficiently.

You must clearly differentiate material which would usually be incorporated in a study editorial from any unprocessed data or additional appendix matter that would not be available. In fact, such matters should not be submitted at all except if requested by the instructor.

Content:

- Sum up your conclusions in text and demonstrate them, if suitable, with figures and tables.
- In the manuscript, explain each of your consequences, and point the reader to remarks that are most appropriate.
- Present a background, such as by describing the question that was addressed by creation of an exacting study.
- Explain results of control experiments and give remarks that are not accessible in a prescribed figure or table, if appropriate.
- Examine your data, then prepare the analyzed (transformed) data in the form of a figure (graph), table, or manuscript.

What to stay away from:

- Do not discuss or infer your outcome, report surrounding information, or try to explain anything.
- Do not include raw data or intermediate calculations in a research manuscript.
- Do not present similar data more than once.
- A manuscript should complement any figures or tables, not duplicate information.
- Never confuse figures with tables—there is a difference.

Approach:

As always, use past tense when you submit your results, and put the whole thing in a reasonable order.

Put figures and tables, appropriately numbered, in order at the end of the report.

If you desire, you may place your figures and tables properly within the text of your results section.

Figures and tables:

If you put figures and tables at the end of some details, make certain that they are visibly distinguished from any attached appendix materials, such as raw facts. Whatever the position, each table must be titled, numbered one after the other, and include a heading. All figures and tables must be divided from the text.

Discussion:

The discussion is expected to be the trickiest segment to write. A lot of papers submitted to the journal are discarded based on problems with the discussion. There is no rule for how long an argument should be.

Position your understanding of the outcome visibly to lead the reviewer through your conclusions, and then finish the paper with a summing up of the implications of the study. The purpose here is to offer an understanding of your results and support all of your conclusions, using facts from your research and generally accepted information, if suitable. The implication of results should be fully described.

Infer your data in the conversation in suitable depth. This means that when you clarify an observable fact, you must explain mechanisms that may account for the observation. If your results vary from your prospect, make clear why that may have happened. If your results agree, then explain the theory that the proof supported. It is never suitable to just state that the data approved the prospect, and let it drop at that. Make a decision as to whether each premise is supported or discarded or if you cannot make a conclusion with assurance. Do not just dismiss a study or part of a study as "uncertain."



Research papers are not acknowledged if the work is imperfect. Draw what conclusions you can based upon the results that you have, and take care of the study as a finished work.

- You may propose future guidelines, such as how an experiment might be personalized to accomplish a new idea.
- Give details of all of your remarks as much as possible, focusing on mechanisms.
- Make a decision as to whether the tentative design sufficiently addressed the theory and whether or not it was correctly restricted. Try to present substitute explanations if they are sensible alternatives.
- One piece of research will not counter an overall question, so maintain the large picture in mind. Where do you go next? The best studies unlock new avenues of study. What questions remain?
- Recommendations for detailed papers will offer supplementary suggestions.

Approach:

When you refer to information, differentiate data generated by your own studies from other available information. Present work done by specific persons (including you) in past tense.

Describe generally acknowledged facts and main beliefs in present tense.

THE ADMINISTRATION RULES

Administration Rules to Be Strictly Followed before Submitting Your Research Paper to Global Journals Inc.

Please read the following rules and regulations carefully before submitting your research paper to Global Journals Inc. to avoid rejection.

Segment draft and final research paper: You have to strictly follow the template of a research paper, failing which your paper may get rejected. You are expected to write each part of the paper wholly on your own. The peer reviewers need to identify your own perspective of the concepts in your own terms. Please do not extract straight from any other source, and do not rephrase someone else's analysis. Do not allow anyone else to proofread your manuscript.

Written material: You may discuss this with your guides and key sources. Do not copy anyone else's paper, even if this is only imitation, otherwise it will be rejected on the grounds of plagiarism, which is illegal. Various methods to avoid plagiarism are strictly applied by us to every paper, and, if found guilty, you may be blacklisted, which could affect your career adversely. To guard yourself and others from possible illegal use, please do not permit anyone to use or even read your paper and file.




CRITERION FOR GRADING A RESEARCH PAPER (COMPILATION)
BY GLOBAL JOURNALS

Please note that following table is only a Grading of "Paper Compilation" and not on "Performed/Stated Research" whose grading solely depends on Individual Assigned Peer Reviewer and Editorial Board Member. These can be available only on request and after decision of Paper. This report will be the property of Global Journals.

Topics	Grades		
	A-B	C-D	E-F
<i>Abstract</i>	Clear and concise with appropriate content, Correct format. 200 words or below	Unclear summary and no specific data, Incorrect form Above 200 words	No specific data with ambiguous information Above 250 words
<i>Introduction</i>	Containing all background details with clear goal and appropriate details, flow specification, no grammar and spelling mistake, well organized sentence and paragraph, reference cited	Unclear and confusing data, appropriate format, grammar and spelling errors with unorganized matter	Out of place depth and content, hazy format
<i>Methods and Procedures</i>	Clear and to the point with well arranged paragraph, precision and accuracy of facts and figures, well organized subheads	Difficult to comprehend with embarrassed text, too much explanation but completed	Incorrect and unorganized structure with hazy meaning
<i>Result</i>	Well organized, Clear and specific, Correct units with precision, correct data, well structuring of paragraph, no grammar and spelling mistake	Complete and embarrassed text, difficult to comprehend	Irregular format with wrong facts and figures
<i>Discussion</i>	Well organized, meaningful specification, sound conclusion, logical and concise explanation, highly structured paragraph reference cited	Wordy, unclear conclusion, spurious	Conclusion is not cited, unorganized, difficult to comprehend
<i>References</i>	Complete and correct format, well organized	Beside the point, Incomplete	Wrong format and structuring





INDEX

A

Adamantinoma · 9, 10
Adolescence · 5
Arthrox · 19, 20, 23

B

Bastichikitsa · 23

C

Clonidine · 12
Congenital · 5, 12
Cortex · 1, 9, 11, 17
Cosmesis · 5

D

Dorsal · 11, 12
Dysplasia · 1, 4, 5, 7, 9, 10

E

Epithelial · 7, 9

F

Femoral · 1

L

Leukotrienes · 23

P

Pallisading · 7
Phantom · 11, 17, 18
Polyostotic · 1, 4
Postzygotic · 4

R

Ropivacaine · 11, 14, 15, 16, 17

S

Sciatic · 13
Sporadic · 4

T

Thalamus · 11, 12, 17
Traumatic · 12

V

Virechana · 19, 20, 23

W

Worsening · 11




save our planet



Global Journal of Medical Research

Visit us on the Web at www.GlobalJournals.org | www.MedicalResearchJournal.org
or email us at helpdesk@globaljournals.org

ISSN 9755896



© Global Journals